

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive

New England Journal of Medicine

363, 1812-1821

DOI: [10.1056/nejmoa1002965](https://doi.org/10.1056/nejmoa1002965)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. <i>Genome Medicine</i> , 2011, 3, 26.	3.6	20
2	More Is Not Necessarily Better When Treating Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 4215-4216.	0.8	5
3	Brentuximab vedotin: delivering an antimetabolic drug to activated lymphoma cells. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 99-105.	1.9	35
4	Analytical methods for physicochemical characterization of antibody drug conjugates. <i>MAbs</i> , 2011, 3, 161-172.	2.6	298
5	Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology. <i>Therapeutic Delivery</i> , 2011, 2, 769-791.	1.2	27
6	<i>In Vitro</i> and <i>In Vivo</i> Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1728-1739.	1.9	102
8	Clinical development of panobinostat in classical Hodgkin's lymphoma. <i>Expert Review of Hematology</i> , 2011, 4, 245-252.	1.0	18
9	An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for CD20 positive tumours. <i>European Journal of Cancer</i> , 2011, 47, 1736-1746.	1.3	38
10	Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates. <i>Cancer Research</i> , 2011, 71, 6300-6309.	0.4	119
11	Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 1222-1228.	5.1	168
12	Histone deacetylase inhibitors and Hodgkin's lymphoma. <i>Lancet Oncology</i> , The, 2011, 12, 1178-1179.	5.1	2
13	Brentuximab Vedotin (SGN-35). <i>Clinical Cancer Research</i> , 2011, 17, 6428-6436.	3.2	333
14	Brentuximab Vedotin and Vemurafenib. <i>Hospital Pharmacy</i> , 2011, 46, 934-942.	0.4	0
15	Hematopoietic Cell Transplantation for Lymphomas. <i>Cancer Control</i> , 2011, 18, 246-257.	0.7	17
16	Molecular Predictors of Response in Aggressive T-cell Lymphomas. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 142-148.	1.0	1
17	CD30-targeted antibody therapy. <i>Current Opinion in Oncology</i> , 2011, 23, 587-593.	1.1	61
18	Targeted Drug Delivery Using Immunoconjugates. <i>Journal of Immunotherapy</i> , 2011, 34, 611-628.	1.2	56
19	How I treat relapsed and refractory Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 4208-4217.	0.6	126

#	ARTICLE	IF	CITATIONS
20	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. <i>Blood</i> , 2011, 118, 4024-4035.	0.6	365
22	The Role of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1060-1071.	2.3	20
23	Antibodies in oncology. <i>New Biotechnology</i> , 2011, 28, 518-529.	2.4	62
24	Human kappa light chain targeted <i>Pseudomonas</i> exotoxin A identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development. <i>Journal of Immunological Methods</i> , 2011, 371, 122-133.	0.6	19
25	Introduction to current and future protein therapeutics: A protein engineering perspective. <i>Experimental Cell Research</i> , 2011, 317, 1261-1269.	1.2	400
26	Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. <i>Leukemia and Lymphoma</i> , 2011, 52, 740-744.	0.6	64
27	Cancer Immunotherapy Comes of Age. <i>Journal of Clinical Oncology</i> , 2011, 29, 4828-4836.	0.8	411
28	Antibody Conjugate Therapeutics: Challenges and Potential. <i>Clinical Cancer Research</i> , 2011, 17, 6389-6397.	3.2	365
30	Antibody therapy for Adult T-cell leukemia-lymphoma. <i>International Journal of Hematology</i> , 2011, 94, 443-452.	0.7	42
31	The Role of Autologous Transplantation in Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 172-179.	1.2	19
32	CD30+ Neoplasms of the Skin. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 245-250.	1.2	64
33	Newly Emerging Therapies Targeting Viral-Related Lymphomas. <i>Current Oncology Reports</i> , 2011, 13, 416-426.	1.8	21
34	Ongoing Development of Monoclonal Antibodies and Antibody Drug-Conjugates in Lymphoma. <i>Current Oncology Reports</i> , 2011, 13, 386-397.	1.8	3
35	Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 851-858.	2.0	7
37	Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. <i>Future Oncology</i> , 2011, 7, 963-979.	1.1	7
38	Treatment for relapsed Hodgkin lymphoma: refinement of chemotherapy or targeted treatment?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 991-994.	0.9	0
39	A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. <i>Blood</i> , 2011, 118, 5119-5125.	0.6	181
40	CD30: an important new target in hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2011, 52, 1641-1654.	0.6	72

#	ARTICLE	IF	CITATIONS
41	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011, 22, vi55-vi58.	0.6	86
42	Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. <i>Bioanalysis</i> , 2011, 3, 677-700.	0.6	74
43	Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1127-1136.	1.9	27
44	SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 6448-6458.	3.2	155
45	New drug therapies in peripheral T-cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 457-472.	1.1	28
46	Optimal Therapy of Advanced Hodgkin Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 310-316.	0.9	21
47	Brentuximab vedotin for the treatment of CD30 ⁺ lymphomas. <i>Immunotherapy</i> , 2011, 3, 475-485.	1.0	37
48	Targeted molecular therapy in peripheral T-cell lymphomas. <i>Expert Review of Hematology</i> , 2011, 4, 551-562.	1.0	10
49	Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. <i>Toxins</i> , 2011, 3, 848-883.	1.5	127
50	Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-24.	3.3	28
51	Targeting Costimulatory Molecules to Improve Antitumor Immunity. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-17.	3.0	71
52	Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 99.	1.2	0
53	Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs. <i>Journal of Investigative Dermatology</i> , 2012, 132, 517-525.	0.3	11
54	Non-Hodgkin's Lymphomas. , 2012, , 1218-1228.		1
55	Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. <i>Oncologist</i> , 2012, 17, 1073-1080.	1.9	42
56	Advances in the Treatment of Relapsed or Refractory Hodgkin's Lymphoma. <i>Oncologist</i> , 2012, 17, 367-376.	1.9	16
57	U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 5845-5849.	3.2	193
58	Current treatment strategies in Hodgkin lymphomas. <i>Current Opinion in Oncology</i> , 2012, 24, 466-474.	1.1	11

#	ARTICLE	IF	CITATIONS
59	Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma. Cancer Journal (Sudbury, Mass) Tj ETQq0 0,0 rgBT /Overlock 10	1.0	41
60	Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood, 2012, 120, 3530-3540.	0.6	122
61	Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Therapeutic Advances in Hematology, 2012, 3, 209-225.	1.1	90
62	The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates. Molecular Cancer Therapeutics, 2012, 11, 1133-1142.	1.9	167
63	Monoclonal Antibodies as Cancer Therapeutics. Recent Patents on Biotechnology, 2012, 6, 45-56.	0.4	6
64	Pharmacotherapy for adult acute lymphoblastic leukemia: an update from recent clinical trials and future directions. Clinical Investigation, 2012, 2, 715-731.	0.0	2
65	Brentuximab vedotin. MAbs, 2012, 4, 458-465.	2.6	116
66	Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leukemia and Lymphoma, 2012, 53, 1239-1241.	0.6	22
67	The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies. Leukemia and Lymphoma, 2012, 53, 2166-2174.	0.6	13
69	Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood, 2012, 120, 560-568.	0.6	157
70	Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d'Étude des Lymphomes de l'Adulte Trials. Journal of Clinical Oncology, 2012, 30, 3939-3946.	0.8	162
71	Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies. Blood Cancer Journal, 2012, 2, e65-e65.	2.8	22
72	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. Leukemia, 2012, 26, 1779-1785.	3.3	14
73	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology, 2012, 30, 3234-3241.	0.8	319
74	Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. Journal of Clinical Oncology, 2012, 30, 3093-3099.	0.8	490
75	Brentuximab vedotin in anaplastic large cell lymphoma. Expert Opinion on Biological Therapy, 2012, 12, 633-639.	1.4	9
76	Costâ€“effectiveness of rituximab in follicular lymphoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 569-577.	0.7	10
77	Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S6637.	0.6	18

#	ARTICLE	IF	CITATIONS
78	Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings. <i>Advances in Hematology</i> , 2012, 2012, 1-7.	0.6	9
79	Advances in the diagnosis and management of lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 29.	1.2	3
80	Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2012, 30, 88-109.	0.8	87
81	Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma. <i>Oncologist</i> , 2012, 17, 80-90.	1.9	27
82	Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. <i>Haematologica</i> , 2012, 97, 1622-1631.	1.7	12
83	Recent advances in novel targeted therapies for HER2-positive breast cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 765-776.	0.7	60
84	Key Lymphoma Takeaways from ASH. <i>Oncology Times</i> , 2012, 34, 13-14.	0.1	0
85	Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 589-597.	2.3	90
86	How to improve efficacy and reduce toxicity in early-stage Hodgkin's lymphoma. <i>International Journal of Hematologic Oncology</i> , 2012, 1, 7-9.	0.7	0
87	Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 1665-1670.	0.6	258
88	Expression of CD30 in patients with acute graft-versus-host disease. <i>Blood</i> , 2012, 120, 691-696.	0.6	47
89	Targeting CD30 in Anaplastic Large Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 285-291.	1.2	7
90	Therapeutic Antibodies Against Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 447-481.	0.9	71
91	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2190-2196.	0.8	890
92	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2183-2189.	0.8	1,332
93	Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. <i>Cancer Science</i> , 2012, 103, 1898-1904.	1.7	16
94	Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Soci�t� Fran�saise de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). <i>British Journal of Haematology</i> , 2012, 158, 649-656.	1.2	31
95	CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 15-22.	1.9	64

#	ARTICLE	IF	CITATIONS
96	Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. <i>Annals of Pharmacotherapy</i> , 2012, 46, 377-383.	0.9	35
97	Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 643-659.	0.8	129
98	Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. <i>Lancet Oncology</i> , The, 2012, 13, 1234-1241.	5.1	208
99	Hodgkin's lymphoma in adults. <i>Lancet</i> , The, 2012, 380, 836-847.	6.3	123
100	Hodgkin lymphoma: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012, 87, 1096-1103.	2.0	34
101	Role of Salvage Radiation Therapy for Patients With Relapsed or Refractory Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e329-e335.	0.4	35
102	RNASSET2 " An autoantigen in anaplastic large cell lymphoma identified by protein array analysis. <i>Journal of Proteomics</i> , 2012, 75, 5279-5292.	1.2	9
103	A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2012, 18, 248-255.	3.2	204
104	Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. <i>Blood</i> , 2012, 120, 1470-1472.	0.6	81
105	Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 506-507.	0.6	15
106	Brentuximab vedotin in systemic T-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 623-632.	1.4	20
107	Adolescents with Hodgkin lymphoma: old children or young adults?. <i>Leukemia and Lymphoma</i> , 2012, 53, 1257-1262.	0.6	10
108	Conjugation of Anticancer Drugs Through Endogenous Monoclonal Antibody Cysteine Residues. <i>Methods in Enzymology</i> , 2012, 502, 123-138.	0.4	92
109	Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2776-2782.	0.8	162
110	Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. <i>Haematologica</i> , 2012, 97, 1073-1079.	1.7	108
111	Profiling Antibody Drug Conjugate Positional Isomers: A System-of-Equations Approach. <i>Analytical Chemistry</i> , 2012, 84, 7479-7486.	3.2	69
112	Epratuzumab "SN-38: A New Antibody "Drug Conjugate for the Therapy of Hematologic Malignancies. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 224-234.	1.9	62
113	Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. <i>Archives of Biochemistry and Biophysics</i> , 2012, 526, 146-153.	1.4	95

#	ARTICLE	IF	CITATIONS
114	Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin's Lymphoma (HL) in the ABVD Therapeutic Era. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 640-647.	2.0	9
115	The Evolving Role of Stem Cell Transplants in Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 660-673.	2.0	28
116	Treatment of newly diagnosed advanced stage Hodgkin lymphoma. <i>Blood Reviews</i> , 2012, 26, 167-174.	2.8	11
117	Brentuximab vedotin in Hodgkin's lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1415-1421.	1.4	17
118	Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 205-216.	1.9	64
119	Pharmacokinetic Considerations for Antibody Drug Conjugates. <i>Pharmaceutical Research</i> , 2012, 29, 2354-2366.	1.7	110
120	From drug discovery to biomarker-driven clinical trials in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 643-653.	12.5	25
121	CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: A matched case-control analysis in a single institution. <i>Journal of Translational Medicine</i> , 2012, 10, 84.	1.8	23
122	Novel therapeutic agents for cutaneous T-Cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2012, 5, 24.	6.9	47
123	Novel CD20 monoclonal antibodies for lymphoma therapy. <i>Journal of Hematology and Oncology</i> , 2012, 5, 64.	6.9	116
124	Engineering Folate-Drug Conjugates to Target Cancer: From Chemistry to Clinic. <i>Bioconjugate Chemistry</i> , 2012, 23, 1357-1369.	1.8	207
125	To Market, To Market—2011. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 499-569.	0.5	23
126	Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2012, 13, 16020-16045.	1.8	40
127	Risks and untoward toxicities of antibody-based immunoconjugates. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1782-1799.	6.6	43
128	Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 280-283.	0.2	30
129	An Unusual Case of Aggressive Systemic Mastocytosis With Associated Refractory Plasma Cell Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 459-462.	0.2	6
130	Brentuximab vedotin ushers in a new era in treating lymphomas. <i>Community Oncology</i> , 2012, 9, 3-4.	0.2	0
131	Brentuximab vedotin in Hodgkin lymphoma and systemic anaplastic large-cell lymphoma. <i>Community Oncology</i> , 2012, 9, 5-7.	0.2	0

#	ARTICLE	IF	CITATIONS
132	Anaplastic large cell lymphoma, ALK-positive. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 293-302.	2.0	98
133	Trial Watch: Monoclonal antibodies in cancer therapy. <i>Oncolimmunology</i> , 2012, 1, 28-37.	2.1	103
134	RECRUIT-TandAbs [®] : harnessing the immune system to kill cancer cells. <i>Future Oncology</i> , 2012, 8, 687-695.	1.1	34
135	PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 355-361.	1.9	34
136	Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. <i>Targeted Oncology</i> , 2012, 7, 199-210.	1.7	28
137	Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 179-185.	1.2	8
138	Recognizing Unusual Manifestations of Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 186-192.	1.2	4
139	Treating T-cell lymphoma: is there a light at the end of the tunnel?. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 174-177.	0.3	0
140	Three-dimensional Telomere Signatures of Hodgkin- and Reed-Sternberg Cells at Diagnosis Identify Patients with Poor Response to Conventional Chemotherapy. <i>Translational Oncology</i> , 2012, 5, 269-277.	1.7	46
141	Advances in the treatment of Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2012, 96, 535-543.	0.7	18
142	Current and future management of NK/T-cell lymphoma based on clinical trials. <i>International Journal of Hematology</i> , 2012, 96, 562-571.	0.7	36
144	Brentuximab vedotin. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 19-20.	21.5	151
145	Novel treatment avenues for peripheral T-cell lymphomas. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 1149-1163.	2.5	4
146	Pre-Clinical Evaluation of a ²¹³ Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication. <i>PLoS ONE</i> , 2012, 7, e31866.	1.1	32
147	Immunotherapy for B-Cell Lymphoma: Current Status and Prospective Advances. <i>Frontiers in Immunology</i> , 2012, 3, 3.	2.2	19
148	Immunotherapy Targets in Pediatric Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 3.	1.3	40
149	Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. <i>The Korean Journal of Hematology</i> , 2012, 47, 8.	0.7	8
150	Hodgkin's Lymphoma. , 2012, , 1228-1233.		1

#	ARTICLE	IF	CITATIONS
151	Survivorship in Hodgkin Lymphoma. , 0, , .		0
152	Targeting CD30 in Hodgkin Lymphoma: Antibody-Drug Conjugates Make a Difference. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 162-166.	1.8	7
153	Hodgkin lymphoma. Journal of Clinical Investigation, 2012, 122, 3439-3447.	3.9	248
154	Lessons from the past: Opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatric Blood and Cancer, 2012, 58, 334-343.	0.8	116
155	Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood, 2012, 119, 4123-4128.	0.6	70
156	State of the art in the treatment of Hodgkin lymphoma. Nature Reviews Clinical Oncology, 2012, 9, 450-459.	12.5	72
157	Using antibodies to target cancer therapeutics. Expert Opinion on Biological Therapy, 2012, 12, 1173-1190.	1.4	19
159	Antibody therapy of cancer. Nature Reviews Cancer, 2012, 12, 278-287.	12.8	1,861
160	The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature Biotechnology, 2012, 30, 631-637.	9.4	637
162	IN16 New drugs for the treatment of lymphomas. Critical Reviews in Oncology/Hematology, 2012, 82, S12.	2.0	0
163	IN17 Survival impact of prophylactic administration of darbepoetin alfa in patients with diffuse large B-cell lymphoma treated with immunochemotherapy: the LNH03-6B study. Critical Reviews in Oncology/Hematology, 2012, 82, S12-S13.	2.0	0
164	Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intentionâ€toâ€treat analysis. British Journal of Haematology, 2012, 157, 201-204.	1.2	9
165	Poor prognosis of <sc>H</sc>odgkin variant of <sc>R</sc>ichter transformation in chronic lymphocytic leukemia treated with cladribine. British Journal of Haematology, 2012, 158, 286-288.	1.2	20
166	Utilizing CD30 expression as a rational target for therapy of lymphoma. Journal of Hematology and Oncology, 2012, 5, .	6.9	2
167	A Traceless Vascularâ€Targeting Antibodyâ€Drug Conjugate for Cancer Therapy. Angewandte Chemie - International Edition, 2012, 51, 941-944.	7.2	113
168	Brentuximab Vedotin in CD30+ Lymphomas. Biologics in Therapy, 2013, 3, 15-23.	1.8	24
170	Highlights of the Third International Conference on Immunotherapy in Pediatric Oncology. Pediatric Hematology and Oncology, 2013, 30, 349-366.	0.3	3
171	High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. The Cochrane Library, 2013, , CD009411.	1.5	57

#	ARTICLE	IF	CITATIONS
172	Antibody-Drug Conjugates. Methods in Molecular Biology, 2013, , .	0.4	24
173	Antibodyâ€“Drug Conjugate (ADC) Clinical Pipeline: A Review. Methods in Molecular Biology, 2013, 1045, 1-27.	0.4	127
174	Nodular Sclerosis Hodgkin Lymphoma. , 2013, , 363-368.		0
175	Resistance to Immunotherapeutic Antibodies in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , .	0.1	2
176	Non-Hodgkin Lymphoma. , 2013, , .		1
177	T-Cell Lymphomas. , 2013, , .		1
178	Characterization of the drug-to-antibody ratio distribution for antibodyâ€“drug conjugates in plasma/serum. Bioanalysis, 2013, 5, 1057-1071.	0.6	98
179	Atlas of Lymph Node Pathology. , 2013, , .		8
180	Whatâ€™s new in Hodgkinâ€™s lymphoma: ASH 2012 and more. Memo - Magazine of European Medical Oncology, 2013, 6, 193-196.	0.3	1
181	Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory Hodgkin lymphoma (HL). Memo - Magazine of European Medical Oncology, 2013, 6, 119-122.	0.3	0
182	Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibodyâ€“drug conjugates. Expert Review of Clinical Pharmacology, 2013, 6, 541-555.	1.3	26
183	BEACOPPescalated versus ABVD in advanced Hodgkin's lymphoma. Lancet Oncology, The, 2013, 14, 911-912.	5.1	3
185	Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin. Annals of Hematology, 2013, 92, 567-568.	0.8	21
186	Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. Annals of Hematology, 2013, 92, 125-127.	0.8	25
188	Progress in the initial management of Hodgkinâ€™s Lymphoma. Transfusion and Apheresis Science, 2013, 49, 12-18.	0.5	3
189	Linker Technologies for Antibodyâ€“Drug Conjugates. Methods in Molecular Biology, 2013, 1045, 71-100.	0.4	89
190	Treatment strategies for peripheral T-cell lymphomas. Best Practice and Research in Clinical Haematology, 2013, 26, 43-56.	0.7	7
192	Current state of art for transplantation paradigms in peripheral T-cell lymphomas. Expert Review of Hematology, 2013, 6, 465-474.	1.0	3

#	ARTICLE	IF	CITATIONS
193	Site-specific chemical modification of antibody fragments using traceless cleavable linkers. <i>Nature Protocols</i> , 2013, 8, 2079-2089.	5.5	67
194	Advanced and Relapsed/Refractory Hodgkin Lymphoma: What Has Been Achieved During the Last 50 Years. <i>Seminars in Hematology</i> , 2013, 50, 4-14.	1.8	25
195	Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 4260-4267.	0.8	83
196	Exploiting Endocytosis for Nanomedicines. <i>Cold Spring Harbor Perspectives in Biology</i> , 2013, 5, a016980-a016980.	2.3	173
197	Antibody Therapeutics in Cancer. <i>Science</i> , 2013, 341, 1192-1198.	6.0	474
198	Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 410-417.	2.0	61
199	Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2013, 6, 62.	6.9	26
200	CD30: from basic research to cancer therapy. <i>Immunologic Research</i> , 2013, 57, 151-158.	1.3	44
201	Mutations and chromosomal rearrangements of <i>JAK2</i> : not only a myeloid issue. <i>Expert Review of Hematology</i> , 2013, 6, 429-439.	1.0	9
202	High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future. <i>Expert Review of Hematology</i> , 2013, 6, 451-464.	1.0	17
203	Strategies to address drug interaction potential for antibody-drug conjugates in clinical development. <i>Bioanalysis</i> , 2013, 5, 1115-1130.	0.6	19
204	CD30 expression in acute myeloid leukemia is associated with <i>FLT3</i> -internal tandem duplication mutation and leukocytosis. <i>Leukemia and Lymphoma</i> , 2013, 54, 860-863.	0.6	15
205	Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma. <i>Expert Review of Hematology</i> , 2013, 6, 361-373.	1.0	6
206	Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 77-84.	1.2	91
207	Children's Oncology Group's 2013 blueprint for research: Non-Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 979-984.	0.8	35
208	Non-Hodgkin lymphoma: the clinician's perspective—a view from the receiving end. <i>Modern Pathology</i> , 2013, 26, S111-S118.	2.9	13
209	Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. <i>Annals of Oncology</i> , 2013, 24, 838-842.	0.6	19
210	Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 216-237.	2.0	93

#	ARTICLE	IF	CITATIONS
211	Brentuximab Vedotin: A <sc>CD</sc>30-directed Antibody-antigen Cytotoxic Drug Conjugate. <i>Pharmacotherapy</i> , 2013, 33, 93-104.	1.2	51
212	NK/T-cell lymphomas in children. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 33-41.	0.7	6
213	Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. <i>Biomaterials</i> , 2013, 34, 8909-8917.	5.7	71
214	Immunologic pathomechanism of Hodgkin's lymphoma. <i>Experimental Hematology</i> , 2013, 41, 995-1004.	0.2	14
215	Allogeneic Stem Cell Transplantation with BEAM and Alemtuzumab Conditioning Immediately after Remission Induction Has Curative Potential in Advanced T-Cell Non-Hodgkin's Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1632-1637.	2.0	23
216	Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment. <i>Journal of Urology</i> , 2013, 190, 1919-1924.	0.2	36
217	Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1740-1744.	2.0	52
218	Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 972-978.	0.8	56
219	Brentuximab Vedotin. <i>Clinical Cancer Research</i> , 2013, 19, 22-27.	3.2	134
220	New drugs for children and adolescents with cancer: the need for novel development pathways. <i>Lancet Oncology</i> , The, 2013, 14, e117-e124.	5.1	81
221	Monoclonal Antibodies (mAb) in the Therapy of T-Cell Lymphomas. , 2013, , 243-261.		0
222	CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 307-314.	0.2	31
223	Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission. <i>Journal of Clinical Oncology</i> , 2013, 31, e59-e63.	0.8	62
224	Treatment of Advanced Hodgkin Lymphoma: The More Things Change, the More They Stay the Same. <i>Journal of Clinical Oncology</i> , 2013, 31, 660-662.	0.8	12
225	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	0.6	206
226	Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2144-2148.	0.6	31
227	Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2013, 54, 2318-2321.	0.6	20
228	Potential therapeutic biomarkers in plasma cell myeloma: A flow cytometry study. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 222-228.	0.7	23

#	ARTICLE	IF	CITATIONS
229	Antibody Drug Conjugates as Cancer Therapeutics. <i>Antibodies</i> , 2013, 2, 113-129.	1.2	83
230	Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure. <i>Drugs</i> , 2013, 73, 371-381.	4.9	27
231	Drug-conjugated antibodies for the treatment of cancer. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 248-262.	1.1	126
232	Monoclonal antibody-based therapies in cancer: Advances and challenges. , 2013, 138, 452-469.		96
233	Development of a diketopiperazine-forming dipeptidyl Gly-Pro spacer for preparation of an antibody-drug conjugate. <i>MedChemComm</i> , 2013, 4, 792.	3.5	19
234	The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). <i>Leukemia and Lymphoma</i> , 2013, 54, 1405-1410.	0.6	27
235	Dose-finding designs using a novel quasi-continuous endpoint for multiple-toxicities. <i>Statistics in Medicine</i> , 2013, 32, 2728-2746.	0.8	45
236	Complete Response of Relapsed Systemic and Cutaneous Anaplastic Large Cell Lymphoma Using Brentuximab Vedotin: 2 Case Reports. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 493-495.	0.2	14
237	Analytical and bioanalytical technologies for characterizing antibody-drug conjugates. <i>Current Opinion in Chemical Biology</i> , 2013, 17, 406-411.	2.8	49
238	Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature. <i>Chemical Science</i> , 2013, 4, 297-302.	3.7	27
239	Engineered Antibody Derivatives in Preclinical and Clinical Development. , 2013, , 251-284.		0
240	The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: A review of the literature and new perspectives. <i>Cancer Treatment Reviews</i> , 2013, 39, 51-59.	3.4	20
241	Development of a Native Nanoelectrospray Mass Spectrometry Method for Determination of the Drug-to-Antibody Ratio of Antibody-Drug Conjugates. <i>Analytical Chemistry</i> , 2013, 85, 1699-1704.	3.2	70
242	Antibody-Drug Conjugates and Immunotoxins. , 2013, , .		5
243	HSV-1 cutaneous infection in a patient with Hodgkin's lymphoma treated with brentuximab vedotin. <i>Journal of Chemotherapy</i> , 2013, 25, 381-382.	0.7	4
244	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. <i>Haematologica</i> , 2013, 98, 1232-1236.	1.7	65
245	Brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: a review of clinical experience and future directions. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 455-465.	0.7	1
246	Brentuximab vedotin: the science of common sense. <i>Leukemia and Lymphoma</i> , 2013, 54, 2089-2090.	0.6	1

#	ARTICLE	IF	CITATIONS
247	Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma. Case Reports in Hematology, 2013, 2013, 1-5.	0.3	3
248	Advanced Targeted, Cell and Gene-Therapy Approaches for Pediatric Hematological Malignancies: Results and Future Perspectives. Frontiers in Oncology, 2013, 3, 106.	1.3	5
249	Antibody Therapy of Pediatric B-Cell Lymphoma. Frontiers in Oncology, 2013, 3, 68.	1.3	3
250	Genomic Instability: The Driving Force behind Refractory/Relapsing Hodgkin's Lymphoma. Cancers, 2013, 5, 714-725.	1.7	18
251	Anaplastic Large-Cell Lymphoma With Aberrant Expression of Multiple Cytokeratins Masquerading As Metastatic Carcinoma of Unknown Primary. Journal of Clinical Oncology, 2013, 31, e443-e445.	0.8	19
252	Mast Cell Sarcoma: A Rare and Aggressive Entity—Report of Two Cases and Review of the Literature. Journal of Clinical Oncology, 2013, 31, e90-e97.	0.8	43
253	Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology, 2013, 2, e26333.	2.1	145
254	Refractory Hodgkin Lymphoma. Current Opinion in Oncology, 2013, 25, 463-469.	1.1	9
255	Novel therapies for peripheral T-cell lymphomas. Therapeutic Advances in Hematology, 2013, 4, 173-187.	1.1	6
256	Les lymphomes cutanés. , 2013, , .		0
257	Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. Future Oncology, 2013, 9, 355-368.	1.1	27
259	Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma. Future Oncology, 2013, 9, 21-29.	1.1	3
260	New Strategies in Hodgkin Lymphoma: Better Risk Profiling and Novel Treatments. Clinical Cancer Research, 2013, 19, 2797-2803.	3.2	17
261	CD30 - the head of TNF-family or a successful story of brentuximab vedotin. Archive of Oncology, 2013, 21, 17-19.	0.2	1
262	MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematology, 2013, 2013, 1-58.	1.6	24
263	Monoclonal antibody therapy for classical Hodgkin lymphoma. Clinical Investigation, 2013, 3, 899-910.	0.0	0
264	Brentuximab vedotin: An anti-CD30 antibody-drug conjugate. American Journal of Health-System Pharmacy, 2013, 70, 589-597.	0.5	33
265	Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma. European Journal of Haematology, 2013, 90, 195-201.	1.1	18

#	ARTICLE	IF	CITATIONS
266	CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody~Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 866-877.	1.0	65
267	Novel multifunctional antibody approved for the treatment of breast cancer. <i>Oncolmmunology</i> , 2013, 2, e24567.	2.1	6
268	Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model. <i>Blood Cancer Journal</i> , 2013, 3, e106-e106.	2.8	28
269	Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. <i>Leukemia</i> , 2013, 27, 1677-1687.	3.3	26
271	Key bioanalytical measurements for antibody~drug conjugate development: PK/PD modelers~ perspective. <i>Bioanalysis</i> , 2013, 5, 989-992.	0.6	19
272	The role of monoclonal antibodies in the treatment of lymphomas. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 227-239.	1.4	4
273	CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. <i>Blood</i> , 2013, 122, 1233-1242.	0.6	82
274	Brentuximab in the Treatment of CD30-Positive Enteropathy-Associated T-Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 137-140.	2.3	24
275	Targeting CD30 in Malignant Tissues: Challenges in Detection and Clinical Applications. <i>Pathobiology</i> , 2013, 80, 252-258.	1.9	13
276	CD30-Targeted Therapy with Brentuximab Vedotin and DLI in a Patient with T-Cell Posttransplantation Lymphoma. <i>Transplantation</i> , 2013, 96, e16-e18.	0.5	7
277	Recommandations pour le traitement des lymphomes T cutan~s. , 2013, , 259-268.		0
278	CD30 expression in peripheral T-cell lymphomas. <i>Haematologica</i> , 2013, 98, e81-e82.	1.7	117
280	Targeted Therapy in Relapsed Classical Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 968-976.	2.3	6
281	CD30-positive malignant lymphomas: time for a change of management?. <i>Haematologica</i> , 2013, 98, 1165-1168.	1.7	8
282	Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. <i>Cancer Management and Research</i> , 2013, 5, 225.	0.9	22
283	Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. <i>OncoTargets and Therapy</i> , 2013, 7, 45.	1.0	15
284	New Insights into Individualized Antimetastatic Therapy. <i>Advanced Techniques in Biology & Medicine</i> , 2013, 1, .	0.1	9
285	Tissue Banking, Bioinformatics, and Electronic Medical Records: The Front-End Requirements for Personalized Medicine. <i>Journal of Oncology</i> , 2013, 2013, 1-12.	0.6	34

#	ARTICLE	IF	CITATIONS
286	Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology. <i>Oncotarget</i> , 2013, 4, 397-412.	0.8	40
287	Surveillance Imaging for Lymphoma: Pros and Cons. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e388-e395.	1.8	11
288	Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. <i>OncoTargets and Therapy</i> , 2014, 7, 2227.	1.0	36
289	Inotuzumab Ozogamicin in the treatment of acute lymphoblastic leukemia. <i>Frontiers in Bioscience - Elite</i> , 2014, E6, 40-45.	0.9	13
290	Antibody-drug conjugates targeting prostate-specific membrane antigen. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 12.	3.0	18
291	Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia. <i>OncoTargets and Therapy</i> , 2014, 7, 1717.	1.0	12
292	PATHOBIOLOGY OF HODGKIN LYMPHOMA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014040.	0.5	13
293	Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma. <i>OncoTargets and Therapy</i> , 2014, 7, 1123.	1.0	7
294	Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 79.	0.4	12
295	HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014050.	0.5	18
296	Opening the door to innovation. <i>MAbs</i> , 2014, 6, 812-819.	2.6	14
297	Antibody"Drug Conjugates Delivering DNA Cytotoxics. , 2014, , 479-490.		1
298	Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. <i>Journal of Translational Medicine</i> , 2014, 12, 347.	1.8	32
299	Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2014, 32, 1246-1257.	1.2	95
300	The novel immunotoxin HM1.24-ETA² induces apoptosis in multiple myeloma cells. <i>Blood Cancer Journal</i> , 2014, 4, e219-e219.	2.8	20
301	Target Therapy in Hematological Malignances: New Monoclonal Antibodies. <i>International Scholarly Research Notices</i> , 2014, 2014, 1-16.	0.9	6
302	Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 151-157.	0.9	9
303	CD30: a new target for ALL?. <i>Leukemia and Lymphoma</i> , 2014, 55, 478-479.	0.6	1

#	ARTICLE	IF	CITATIONS
304	Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 969-980.	1.1	28
305	Current therapy of choice for cutaneous lymphomas: Complementary to the Japanese Dermatological Association/Japanese Skin Cancer Society guidelines. <i>Journal of Dermatology</i> , 2014, 41, 43-49.	0.6	8
306	Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 367-383.	1.0	4
307	Immunotherapy in pediatric malignancies: current status and future perspectives. <i>Future Oncology</i> , 2014, 10, 1659-1678.	1.1	11
308	Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 579-586.	0.8	37
309	Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma. <i>Cancer Science</i> , 2014, 105, 840-846.	1.7	48
310	Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. <i>European Journal of Haematology</i> , 2014, 93, 455-468.	1.1	38
311	ACR appropriateness Criteria® pediatric Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1305-1312.	0.8	16
312	Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2014, 55, 1053-1060.	0.6	12
313	MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1599-1610.	1.9	21
314	Primary spleen extranodal NK/T cell lymphoma, nasal type, with bone marrow involvement and CD30 positive expression: a case report and literature review. <i>Diagnostic Pathology</i> , 2014, 9, 169.	0.9	14
315	Antibody-drug conjugates in lymphoma. <i>Clinical Investigation</i> , 2014, 4, 915-922.	0.0	0
316	Antibody drug conjugates. <i>Current Opinion in Oncology</i> , 2014, 26, 476-483.	1.1	16
317	Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma. <i>Current Opinion in Hematology</i> , 2014, 21, 297-308.	1.2	8
318	Specific and Sensitive Tumor Imaging Using Biostable Oligonucleotide Aptamer Probes. <i>Theranostics</i> , 2014, 4, 945-952.	4.6	35
320	CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 624-627.	0.6	35
321	Successful Desensitization to Brentuximab Vedotin After Anaphylaxis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e73-e75.	0.2	15
322	Management of Relapses After Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin Lymphomas. <i>Seminars in Hematology</i> , 2014, 51, 73-86.	1.8	10

#	ARTICLE	IF	CITATIONS
323	CD30 in Systemic Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 341-355.	0.7	21
324	Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody-Drug Conjugates: Focus on Brentuximab Vedotin. <i>BioDrugs</i> , 2014, 28, 245-251.	2.2	11
325	Molecular genetics of peripheral T-cell lymphomas. <i>International Journal of Hematology</i> , 2014, 99, 219-226.	0.7	27
326	Role of CD30 Targeting in Malignant Lymphoma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 210-225.	1.3	19
327	Management of Metastatic Breast Cancer with Second-Generation Antibody-Drug Conjugates: Focus on Glembatumumab Vedotin (CDX-011, CRO11-vcMMAE). <i>BioDrugs</i> , 2014, 28, 253-263.	2.2	22
328	Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. <i>Journal of Clinical Oncology</i> , 2014, 32, 798-808.	0.8	433
329	Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 3796-3827.	7.2	779
330	Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. <i>British Journal of Haematology</i> , 2014, 165, 300-315.	1.2	24
331	Antibody-Dependent Cellular Cytotoxicity (ADCC). , 2014, , 1-27.		22
332	An overview of clinical and commercial impact of drug delivery systems. <i>Journal of Controlled Release</i> , 2014, 190, 15-28.	4.8	379
333	Trends in cancer-targeted antibody-drug conjugates. <i>Targeted Oncology</i> , 2014, 9, 1-8.	1.7	7
334	BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. <i>Leukemia</i> , 2014, 28, 1861-1871.	3.3	48
335	Antibody-drug conjugates: current status and future directions. <i>Drug Discovery Today</i> , 2014, 19, 869-881.	3.2	380
336	Statistical Modeling of the Drug Load Distribution on Trastuzumab Emtansine (Kadcyla), a Lysine-Linked Antibody Drug Conjugate. <i>Bioconjugate Chemistry</i> , 2014, 25, 1223-1232.	1.8	123
337	New drugs and targeted treatments in Hodgkin's lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 457-464.	3.4	10
338	Peripheral T-cell lymphoma: The role of hematopoietic stem cell transplantation. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 248-261.	2.0	28
339	Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. <i>Bone Marrow Transplantation</i> , 2014, 49, 599-606.	1.3	28
340	Production of Site-Specific Antibody-Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System. <i>Bioconjugate Chemistry</i> , 2014, 25, 351-361.	1.8	303

#	ARTICLE	IF	CITATIONS
341	Brentuximab Vedotin for the Treatment of Patients with Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 27-32.	0.9	15
342	Customized Targeted Therapy in Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 105-122.	0.9	6
343	Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 1080-1088.	3.4	58
344	Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 911-924.	1.9	17
345	Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3619-3625.	0.8	94
346	Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. <i>Cancer</i> , 2014, 120, 1993-1999.	2.0	36
347	Quantitative implementation of the endogenous molecular "cellular network hypothesis in hepatocellular carcinoma. <i>Interface Focus</i> , 2014, 4, 20130064.	1.5	26
348	From Monoclonal Antibodies to Chimeric Antigen Receptors for the Treatment of Human Malignancies. <i>Seminars in Oncology</i> , 2014, 41, 661-666.	0.8	54
349	An update on emerging drugs for Hodgkin lymphoma. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 215-224.	1.0	7
350	Advances in biology and therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 628-630.	12.5	3
351	The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. <i>Nature Chemical Biology</i> , 2014, 10, 768-773.	3.9	157
353	Absorption, Distribution, Metabolism, and Excretion Considerations for the Development of Antibody-Drug Conjugates. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1914-1920.	1.7	76
354	Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2014, 93, 1-8.	1.1	11
357	The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2014, 167, 514-523.	1.2	25
358	Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 7261-7269.	1.5	135
359	Antibody-drug conjugates: an emerging modality for the treatment of cancer. <i>Annals of the New York Academy of Sciences</i> , 2014, 1321, 41-54.	1.8	71
360	Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3659-3666.	0.8	72
361	Cystine-knot peptides: emerging tools for cancer imaging and therapy. <i>Expert Review of Proteomics</i> , 2014, 11, 561-572.	1.3	39

#	ARTICLE	IF	CITATIONS
362	Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 399-410.	1.1	69
365	Current status of prognostication in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 165, 287-299.	1.2	27
366	From empiric to mechanism-based therapy for peripheral T cell lymphoma. <i>International Journal of Hematology</i> , 2014, 99, 249-262.	0.7	16
367	CD30 as a Therapeutic Target for Lymphoma. <i>BioDrugs</i> , 2014, 28, 181-209.	2.2	32
368	Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 154-163.	2.0	36
369	Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2014, 32, 187-191.	0.8	42
370	High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: A systematic review with meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 1-10.	2.0	29
371	The Changing Landscape of Peripheral T-Cell Lymphoma in the Era of Novel Therapies. <i>Seminars in Hematology</i> , 2014, 51, 25-34.	1.8	27
372	Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury. <i>Journal of Controlled Release</i> , 2014, 174, 15-26.	4.8	100
373	Reprint of: Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S8-S17.	2.0	3
374	Relapsed Hodgkin Lymphoma: Management Strategies. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 284-293.	1.2	15
375	Microtubule-Depolymerizing Agents Used in Antibody-Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. <i>Cancer Immunology Research</i> , 2014, 2, 741-755.	1.6	134
376	Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. <i>Leukemia and Lymphoma</i> , 2014, 55, 2328-2334.	0.6	48
377	18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 811-816.	0.6	18
378	Management of Advanced NK/T-Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 233-242.	1.2	10
379	State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines. <i>Journal of Controlled Release</i> , 2014, 187, 133-144.	4.8	434
380	A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 213-220.	3.2	105
381	Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2014, 89, 771-779.	2.0	28

#	ARTICLE	IF	CITATIONS
382	Cutaneous CD30-Positive Lymphoproliferative Disorders. <i>Surgical Pathology Clinics</i> , 2014, 7, 203-228.	0.7	57
383	Multiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 465-471.	2.3	24
384	Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. <i>Frontiers in Chemistry</i> , 2014, 2, 69.	1.8	116
386	Tet2-mutated myeloid progenitors possess aberrant in vitro self-renewal capacity. <i>Blood</i> , 2014, 123, 2897-2899.	0.6	12
387	Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. <i>Blood</i> , 2014, 123, 2895-2897.	0.6	52
388	Time has come for immunotherapy in PTCL. <i>Blood</i> , 2014, 123, 3059-3060.	0.6	5
389	Brentuximab vedotin. <i>Blood</i> , 2014, 124, 3197-3200.	0.6	81
390	Computational Construction of Antibody-Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker. <i>Cancer Informatics</i> , 2014, 13, CIN.S19222.	0.9	8
391	Toxicity of targeted therapeutic agents in lymphoma and management: part 1: monoclonal antibodies and radioimmunotherapy. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 41-51.	0.7	0
393	Hodgkin lymphoma in children and adolescents: improving the therapeutic index. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 514-521.	0.9	9
394	Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. <i>Journal of Pathology</i> , 2015, 237, 4-13.	2.1	30
396	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Oncologist</i> , 2015, 20, 1247-1252.	1.9	28
399	Antibody-drug conjugates as novel anti-cancer chemotherapeutics. <i>Bioscience Reports</i> , 2015, 35, .	1.1	327
400	How I treat advanced classical Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 1717-1723.	0.6	23
401	Hodgkin lymphoma in children and adolescents: improving the therapeutic index. <i>Blood</i> , 2015, 126, 2452-2458.	0.6	50
402	Biologic Agents in the Management of Hodgkin Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 587-596.	2.3	4
403	Microsatellite Instability. , 2015, , 2842-2845.		0
404	Licensed monoclonal antibodies and associated challenges. <i>Human Antibodies</i> , 2015, 23, 63-72.	0.6	10

#	ARTICLE	IF	CITATIONS
405	Hodgkin Lymphoma, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 554-586.	2.3	37
406	Primary cutaneous T-cell lymphoma presenting as mycosis fungoides with a T-/null-cell phenotype: report of two cases. British Journal of Dermatology, 2015, 172, 1637-1641.	1.4	6
407	Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma. European Journal of Haematology, 2015, 95, 361-364.	1.1	18
408	Targeted Delivery of Proteasome Inhibitors to Somatostatinâ€Receptorâ€Expressing Cancer Cells by Octreotide Conjugation. ChemMedChem, 2015, 10, 1969-1973.	1.6	3
409	Anticancer Drug Combinations, A Big Momentum is Needed. Metabolomics: Open Access, 2015, 05, .	0.1	2
410	Novel Treatments for T-Cell Lymphoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e468-e478.	1.8	1
411	Novel Agents in the Therapy of Hodgkin Lymphoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e479-e482.	1.8	2
412	CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2015, 7, e2015015.	0.5	14
413	Primary bone lymphoma with multifocal osteolytic lesions: a rare case report with review of literature. Blood Research, 2015, 50, 256.	0.5	5
414	ALK-positive anaplastic large cell lymphoma an evolving story. Frontiers in Bioscience - Scholar, 2015, 7, 248-259.	0.8	5
415	What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e117-e125.	1.8	13
416	Hodgkin lymphoma in children and adolescents: improving the therapeutic index. Hematology American Society of Hematology Education Program, 2015, 2015, 514-521.	0.9	4
417	Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy. Pharmaceuticals, 2015, 8, 607-636.	1.7	15
418	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. Frontiers in Oncology, 2015, 5, 152.	1.3	26
419	Anaplastic Large-Cell Lymphoma in Aids. Baylor University Medical Center Proceedings, 2015, 28, 378-380.	0.2	1
420	Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. Blood Research, 2015, 50, 254.	0.5	60
422	Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	12
423	Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy. Journal of Immunology Research, 2015, 2015, 1-7.	0.9	15

#	ARTICLE	IF	CITATIONS
425	Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma. <i>Molecular Immunology</i> , 2015, 67, 89-94.	1.0	12
426	Linker Design for Antibody-Drug Conjugates. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015, , 49-76.	0.2	1
427	The GHSG Approach to Treating Hodgkin's Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 256-265.	1.2	5
428	Costimulation in Lymphomas and Cancers. , 2015, , 185-254.		7
429	A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 4024-4031.	0.6	265
430	Antibody Drug Conjugates: Nonclinical Safety Considerations. <i>AAPS Journal</i> , 2015, 17, 1055-1064.	2.2	80
431	Hodgkin's lymphoma: who needs consolidation treatment?. <i>Lancet, The</i> , 2015, 385, 1810-1812.	6.3	5
432	Brentuximab vedotin for the treatment of Hodgkin's lymphoma. <i>Expert Review of Hematology</i> , 2015, 8, 403-412.	1.0	8
435	ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. <i>Journal of Hematology and Oncology</i> , 2015, 8, 129.	6.9	223
436	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 507-513.	0.2	13
437	Immunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphoma. <i>Radiology and Oncology</i> , 2015, 49, 315-319.	0.6	1
438	Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 295-307.	1.1	16
439	Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies. <i>Cancer Drug Discovery and Development</i> , 2015, , 245-258.	0.2	0
440	Brentuximab: a major advance in treatment of CD30-positive malignancies. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 219-232.	0.7	0
441	Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. <i>British Journal of Haematology</i> , 2015, 168, 771-783.	1.2	43
442	<sc>H</sc>odgkin transformation of chronic lymphocytic leukemia: <sc>I</sc>ncidence, outcomes, and comparison to <i>de novo</i> <sc>H</sc>odgkin lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 334-338.	2.0	69
443	Individualized cancer chemotherapy via cancer biomarkers or bioinformatics detection. , 2015, , 13-19.		0
444	Individualized antimetastatic therapy [1-2]. , 2015, , 29-36.		0

#	ARTICLE	IF	CITATIONS
445	Drug combinations. , 2015, , 37-41.		5
446	PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 284-292.	5.1	230
447	Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines. <i>Drug Delivery</i> , 2016, 23, 1-5.	2.5	15
448	Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 451-459.	1.5	8
449	The double-edged sword: Neurotoxicity of chemotherapy. <i>Blood Reviews</i> , 2015, 29, 93-100.	2.8	117
451	Advances in Anticancer Immunotoxin Therapy. <i>Oncologist</i> , 2015, 20, 176-185.	1.9	161
452	Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. <i>Prostate</i> , 2015, 75, 303-313.	1.2	31
453	Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. <i>Pharmaceutical Research</i> , 2015, 32, 3470-3479.	1.7	84
454	Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkin's Lymphoma in First Remission. <i>Current Treatment Options in Oncology</i> , 2015, 16, 34.	1.3	5
455	Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. <i>Leukemia and Lymphoma</i> , 2015, 56, 1778-1786.	0.6	48
456	Mortality Patterns Among Recipients of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Myeloma in the Past Three Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 409-415.e1.	0.2	21
457	Non-Hodgkin Lymphoma in Children. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 237-243.	1.2	29
458	The new therapeutical scenario of Hodgkin lymphoma. <i>Annals of Oncology</i> , 2015, 26, 2026-2033.	0.6	21
459	Cancer Immunotherapy Confers a Global Benefit. , 2015, , 1-39.		0
460	Gene Expression Profiling in Non-Hodgkin Lymphomas. <i>Cancer Treatment and Research</i> , 2015, 165, 97-123.	0.2	3
461	A rapid approach for characterization of thiol-conjugated antibody-drug conjugates and calculation of drug-antibody ratio by liquid chromatography mass spectrometry. <i>Analytical Biochemistry</i> , 2015, 485, 34-42.	1.1	38
462	Immune Modulation in Hematologic Malignancies. <i>Seminars in Oncology</i> , 2015, 42, 617-625.	0.8	22
463	Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers. <i>Oncologist</i> , 2015, 20, 323-328.	1.9	29

#	ARTICLE	IF	CITATIONS
464	Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line <sc>ABVD</sc> chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. British Journal of Haematology, 2015, 170, 179-184.	1.2	69
465	Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncology, The, 2015, 16, 704-715.	5.1	272
466	Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma. Drug Design, Development and Therapy, 2015, 9, 1729.	2.0	16
467	Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Investigational Drugs, 2015, 24, 897-912.	1.9	12
468	PET-adapted salvage therapy in Hodgkin's lymphoma. Lancet Oncology, The, 2015, 16, 239-240.	5.1	3
470	Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia, 2015, 29, 1578-1586.	3.3	131
471	Lymphoma in older patients: clinical and therapeutic characteristics. Reviews in Clinical Gerontology, 2015, 25, 1-11.	0.5	0
472	Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents. British Journal of Haematology, 2015, 169, 647-660.	1.2	19
473	Antibody-Drug Conjugates. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , .	0.2	7
474	Brentuximab vedotin for the treatment of Hodgkin's and non-Hodgkin's lymphoma. Expert Opinion on Orphan Drugs, 2015, 3, 609-618.	0.5	0
475	Changing treatment paradigms in lymphoma: new targets and new drugs. Memo - Magazine of European Medical Oncology, 2015, 8, 184-188.	0.3	0
476	Monoclonal Antibodies. Dermatologic Clinics, 2015, 33, 777-786.	1.0	19
477	Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic Proceedings, 2015, 90, 1574-1583.	1.4	120
478	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Molecular Oncology, 2015, 9, 2043-2053.	2.1	87
479	Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma. Current Oncology Reports, 2015, 17, 41.	1.8	31
480	A phase 1 dose-escalation study of XmAb [®] 2513 in patients with relapsed or refractory Hodgkin lymphoma. British Journal of Haematology, 2015, 168, 902-904.	1.2	11
481	Severe cytokine release syndrome after the first dose of <sc>B</sc>rentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (s<sc>ALCL</sc>): a case report and review of literature. European Journal of Haematology, 2015, 94, 554-557.	1.1	27
482	Results of a Phase II Trial of Brentuximab Vedotin for CD30 ⁺ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. Journal of Clinical Oncology, 2015, 33, 3759-3765.	0.8	255

#	ARTICLE	IF	CITATIONS
483	AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. <i>Journal of Hematology and Oncology</i> , 2015, 8, 96.	6.9	84
484	Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 438-447.	1.2	0
485	Brentuximab vedotin: axonal microtubule™s Apollyon. <i>Blood Cancer Journal</i> , 2015, 5, e343-e343.	2.8	22
486	Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma. <i>Biomarkers in Medicine</i> , 2015, 9, 807-817.	0.6	10
487	Field Guide to Challenges and Opportunities in Antibody–Drug Conjugates for Chemists. <i>Bioconjugate Chemistry</i> , 2015, 26, 2198-2215.	1.8	75
488	Novel agents for the treatment of Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2015, 8, 659-667.	1.0	4
489	Coming of Age. <i>Clinics in Plastic Surgery</i> , 2015, 42, 605-613.	0.7	79
490	Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1529-1531.	2.0	4
491	Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 104.	6.9	139
492	Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. <i>Journal of Controlled Release</i> , 2015, 200, 138-157.	4.8	1,477
493	Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 137-145.	0.6	7
494	Peripheral T-cell and <scp>NK</scp> cell lymphoproliferative disorders: cell of origin, clinical and pathological implications. <i>Immunological Reviews</i> , 2015, 263, 124-159.	2.8	30
495	Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. <i>Prostate</i> , 2015, 75, 242-254.	1.2	75
496	Antibody-targeted drugs and drug resistance—Challenges and solutions. <i>Drug Resistance Updates</i> , 2015, 18, 36-46.	6.5	113
497	Pediatric Lymphomas and Histiocytic Disorders of Childhood. <i>Pediatric Clinics of North America</i> , 2015, 62, 139-165.	0.9	77
498	Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. <i>Leukemia</i> , 2015, 29, 448-455.	3.3	43
499	Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 1949-1958.	0.6	48
500	Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. <i>Annals of Oncology</i> , 2015, 26, 386-392.	0.6	44

#	ARTICLE	IF	CITATIONS
502	Multiplex LCMS Bioanalysis of Brentuximab Vedotin, Rituximab and Cetuximab towards Therapeutic Drug Monitoring Application by Combined Calibration Curve Using Fab-Selective Limited Proteolysis nSMOL. <i>Clinical Pharmacology & Biopharmaceutics</i> , 2016, 05, .	0.2	6
504	Recent advances in the management of Hodgkin lymphoma. <i>F1000Research</i> , 2016, 5, 768.	0.8	4
505	Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2016, 56, 50-54.	0.3	3
506	Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application. , 2016, , 813-869.		5
507	Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. <i>World Journal of Gastroenterology</i> , 2016, 22, 6484.	1.4	67
508	Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e354-e366.	1.8	4
509	The emerging role of CD30 and p53 as novel targets for therapy in anaplastic large cell lymphoma. <i>Frontiers in Bioscience - Elite</i> , 2016, 8, 61-71.	0.9	0
510	Rapidly Progressing Refractory Hodgkin Lymphoma: A Case Report and a Possible Explanation. <i>Case Reports in Medicine</i> , 2016, 2016, 1-4.	0.3	2
511	Relapse Pattern and Treatment Outcome of Curative Radiotherapy for Primary Cutaneous CD30+ Anaplastic Large-cell Lymphoma: A Retrospective Cohort Study. <i>Acta Dermato-Venereologica</i> , 2016, 96, 394-395.	0.6	4
512	DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents. <i>Molecules</i> , 2016, 21, 1741.	1.7	6
513	Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future. <i>Pharmaceuticals</i> , 2016, 9, 28.	1.7	7
515	Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 23-26.	1.0	23
516	From the Guest Editor. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 1-2.	1.0	0
517	Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3293-3299.	0.8	90
519	Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. <i>British Journal of Haematology</i> , 2016, 173, 503-504.	1.2	11
520	<sc>CD</sc>30 expression and its correlation with <i><sc>MYC</sc></i> rearrangement in <i>de novo</i> diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2016, 97, 39-47.	1.1	16
522	Neurological sequelae of cancer immunotherapies and targeted therapies. <i>Lancet Oncology</i> , The, 2016, 17, e529-e541.	5.1	71
525	Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. <i>Immunotherapy</i> , 2016, 8, 1335-1346.	1.0	9

#	ARTICLE	IF	CITATIONS
526	Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30 ⁺ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. <i>Haematologica</i> , 2016, 101, 466-473.	1.7	35
527	Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 331-338.	0.9	14
528	Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 589-597.	0.9	60
529	Myeloid Cell Leukemia Sequence 1. , 2016, , 2989-2989.		0
530	Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. <i>MAbs</i> , 2016, 8, 659-671.	2.6	340
531	Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma. <i>International Journal of Hematology</i> , 2016, 104, 396-399.	0.7	6
532	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016, 34, 1175-1181.	0.8	94
533	Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas. <i>Surgical Pathology Clinics</i> , 2016, 9, 41-54.	0.7	5
534	Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?. <i>Current Opinion in Immunology</i> , 2016, 40, vii-xiii.	2.4	20
535	Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. <i>Leukemia and Lymphoma</i> , 2016, 57, 1021-1032.	0.6	119
536	A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 875-882.	1.0	22
537	Targeting Programmed Death 1/Programmed Death Ligand 1 in Lymphoma: A Game Changer. <i>Journal of Oncology Practice</i> , 2016, 12, 107-108.	2.5	1
538	Phase I Study of the Investigational Anti-Guanlyl Cyclase Antibodyâ€“Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies. <i>Clinical Cancer Research</i> , 2016, 22, 5049-5057.	3.2	32
539	How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant. <i>Blood</i> , 2016, 127, 287-295.	0.6	25
540	CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy. <i>Tumor Biology</i> , 2016, 37, 13077-13090.	0.8	36
541	Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5069-5072.	1.0	34
542	CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 480-491.	1.2	17
543	Lymphoma in Adolescents and Young Adults. <i>Progress in Tumor Research</i> , 2016, 43, 101-114.	0.1	9

#	ARTICLE	IF	CITATIONS
545	Tissue distribution and tumor uptake of folate receptor-targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration. <i>Acta Pharmaceutica Sinica B</i> , 2016, 6, 460-467.	5.7	13
546	<i>Pediatric Leukemias and Lymphomas.</i> , 2016, , 1455-1463.e3.		0
547	<i>Pediatric Hodgkin's Lymphoma.</i> , 2016, , 1464-1485.e5.		0
548	Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 567-582.	0.8	81
549	Practical Considerations for Clinical Pharmacology in Drug Development: A Survey of 44 FDA Oncology Approvals. , 2016, , 237-301.		1
550	Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy. <i>Biomacromolecules</i> , 2016, 17, 3602-3608.	2.6	35
554	Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity. <i>Oncolmmunology</i> , 2016, 5, e1211221.	2.1	4
555	Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients. <i>Oncologist</i> , 2016, 21, 1436-1441.	1.9	15
556	Chemotherapy remains an essential element of personalized care for persons with lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1829-1835.	0.6	83
557	Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 696-705.	1.1	49
558	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. <i>British Journal of Pharmacology</i> , 2016, 173, 1407-1424.	2.7	56
559	Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond. <i>American Journal of Hematology</i> , 2016, 91, 109-112.	2.0	20
560	Challenges and advances in the assessment of the disposition of antibody-drug conjugates. <i>Biopharmaceutics and Drug Disposition</i> , 2016, 37, 66-74.	1.1	44
561	Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy. <i>Pharmacotherapy</i> , 2016, 36, 99-116.	1.2	41
562	Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 55.	1.3	17
563	ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. <i>Annals of Hematology</i> , 2016, 95, 1725-1726.	0.8	15
564	Expanding the Reach of Antibody-Drug Conjugates. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 974-976.	1.3	58
565	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. <i>Blood</i> , 2016, 128, 1458-1464.	0.6	61

#	ARTICLE	IF	CITATIONS
566	Handbook of Lymphoma. , 2016, , .		3
567	Structural Characterization of Cross-Linked Species in Trastuzumab Emtansine (Kadcyla). Bioconjugate Chemistry, 2016, 27, 2037-2047.	1.8	27
568	New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma. Expert Review of Hematology, 2016, 9, 767-780.	1.0	11
569	Hodgkin lymphoma: 2016 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2016, 91, 434-442.	2.0	84
573	Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology, 2016, 78, 1217-1223.	1.1	20
574	Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic. Regulatory Toxicology and Pharmacology, 2016, 82, 1-13.	1.3	33
575	Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibodyâ€Drug Conjugation Chemistry. ChemMedChem, 2016, 11, 2501-2505.	1.6	16
576	15. Anaplastic large cell lymphoma. , 2016, , 285-310.		0
577	Prostate-Specific Membrane Antigenâ€Directed Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 347-352.	1.0	11
578	Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, , .	0.8	6
579	Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. International Journal of Hematology, 2016, 104, 236-244.	0.7	17
580	Antibodyâ€drug conjugates for cancer therapy. Lancet Oncology, The, 2016, 17, e254-e262.	5.1	439
581	Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results. Seminars in Hematology, 2016, 53, 186-189.	1.8	26
582	Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation. Regulatory Toxicology and Pharmacology, 2016, 79, S79-S93.	1.3	20
583	Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 70.	3.5	15
584	Richter transformation of CLL. Expert Review of Hematology, 2016, 9, 793-801.	1.0	32
585	Clinical response to everolimus in a patient with Hodgkinâ€™s lymphoma harboring a TSC2 mutation. Blood Cancer Journal, 2016, 6, e420-e420.	2.8	7
586	Childhood, adolescent and young adult nonâ€Hodgkin lymphoma: state of the science. British Journal of Haematology, 2016, 173, 507-530.	1.2	30

#	ARTICLE	IF	CITATIONS
587	The future of antiviral immunotoxins. <i>Journal of Leukocyte Biology</i> , 2016, 99, 911-925.	1.5	24
588	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 214-227.	2.0	31
589	Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine. <i>Annals of Hematology</i> , 2016, 95, 847-849.	0.8	45
590	Structural characterization of antibody drug conjugate by a combination of intact, middle-up and bottom-up techniques using sheathless capillary electrophoresis and Tandem mass spectrometry as nanoESI infusion platform and separation method. <i>Analytica Chimica Acta</i> , 2016, 918, 50-59.	2.6	70
591	Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1624-1629.	3.3	38
592	Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 279-283.	1.1	6
593	Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. <i>Cancer Research</i> , 2016, 76, 2710-2719.	0.4	202
594	Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1301-1310.	1.9	58
595	New developments for antibody-drug conjugate-based therapeutic approaches. <i>Current Opinion in Immunology</i> , 2016, 40, 14-23.	2.4	225
596	Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 49-56.	0.2	44
597	Recent advances in the construction of antibody-drug conjugates. <i>Nature Chemistry</i> , 2016, 8, 114-119.	6.6	289
598	A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e15-e19.	0.2	16
599	Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 859-867.	1.5	15
600	Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 347-364.	1.4	4
601	Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 160-168.	0.8	349
602	Hodgkin's Lymphoma. , 2016, , 1506-1523.e5.		0
603	Cancer-treatment-induced neurotoxicity—focus on newer treatments. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 92-105.	12.5	189
604	New Life for Immunotoxin Cancer Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 1055-1058.	3.2	38

#	ARTICLE	IF	CITATIONS
605	Umbilical cord blood transplantation in adults with advanced Hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. <i>European Journal of Haematology</i> , 2016, 96, 128-135.	1.1	19
606	Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 188-192.	0.5	7
607	Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 600-609.	2.0	99
608	Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering. <i>Chemical Science</i> , 2017, 8, 2056-2060.	3.7	52
609	Immunotoxin: A new tool for cancer therapy. <i>Tumor Biology</i> , 2017, 39, 101042831769222.	0.8	99
611	TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets. <i>MAbs</i> , 2017, 9, 603-614.	2.6	23
612	Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lymphoproliferative disorders: a single centre experience. <i>Internal Medicine Journal</i> , 2017, 47, 574-578.	0.5	11
613	Inducible, Site-Specific Protein Labeling by Tyrosine Oxidation-Strain-Promoted (4 + 2) Cycloaddition. <i>Bioconjugate Chemistry</i> , 2017, 28, 1189-1193.	1.8	71
614	Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. <i>Investigational New Drugs</i> , 2017, 35, 235-241.	1.2	16
615	Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 47-56.	0.6	7
616	Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1074-1077.	1.3	38
617	Stable and Homogeneous Drug Conjugation by Sequential Bis-Alkylation at Disulphide Bonds Using Bis-Sulphone Reagents. <i>Milestones in Drug Therapy</i> , 2017, , 47-67.	0.1	0
621	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. <i>Cancer Journal (Sudbury, Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	1.0	8
622	Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e263-e266.	0.3	38
624	Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sazary Syndrome. <i>Journal of Neuro-Oncology</i> , 2017, 132, 439-446.	1.4	33
625	Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. <i>BioDrugs</i> , 2017, 31, 151-166.	2.2	58
626	Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. <i>Protein and Cell</i> , 2017, 8, 896-925.	4.8	59
627	A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. <i>Investigational New Drugs</i> , 2017, 35, 634-641.	1.2	25

#	ARTICLE	IF	CITATIONS
628	Use of the basophil activation test in monitoring clinical tolerance after desensitization to brentuximab vedotin. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 745-747.	0.5	7
629	Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. <i>Cancer</i> , 2017, 123, 3763-3771.	2.0	25
630	Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1393-1401.	0.5	79
631	Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1208-1211.	1.3	8
632	Cell Division Machinery and Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	4
633	Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1148-1158.	1.0	36
634	Clinical Development of Anti-mitotic Drugs in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1002, 125-152.	0.8	22
635	NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma. <i>Aesthetic Surgery Journal</i> , 2017, 37, 285-289.	0.9	171
636	Immunotherapy for the treatment of Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 417-423.	1.0	12
637	Future of Drug Discovery. , 2017, , 609-629.		3
638	Adult T-cell Leukemia/Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 255-272.	0.9	15
639	Nivolumab before and after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1054-1056.	1.3	15
640	Antibodies and associates: Partners in targeted drug delivery. , 2017, 177, 129-145.		52
641	Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1388-1397.	1.4	21
642	Developments and future clinical outlook of taxane nanomedicines. <i>Journal of Controlled Release</i> , 2017, 253, 137-152.	4.8	34
643	Novel agents in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2275-2286.	0.6	14
644	Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. , 2017, , .		13
645	Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 109, 42-50.	2.0	59

#	ARTICLE	IF	CITATIONS
646	A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. <i>Seminars in Diagnostic Pathology</i> , 2017, 34, 22-35.	1.0	47
647	The landscape of new drugs in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 335-346.	12.5	56
648	Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 29-37.	1.0	43
649	Novel treatment concepts in Hodgkin lymphoma. <i>Journal of Internal Medicine</i> , 2017, 281, 247-260.	2.7	32
650	Classic Hodgkin lymphoma in pelvis. <i>Medicine (United States)</i> , 2017, 96, e8196.	0.4	5
651	Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. <i>Cancer Treatment Reviews</i> , 2017, 60, 120-129.	3.4	38
652	Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 293-302.	1.1	19
653	Role of stem cell transplant in lymphoma in the era of new drugs. <i>Current Opinion in Oncology</i> , 2017, 29, 455-459.	1.1	10
654	Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management. <i>Future Oncology</i> , 2017, 13, 2405-2411.	1.1	14
655	Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future. <i>Journal of Clinical Pharmacology</i> , 2017, 57, S11-S25.	1.0	37
656	Antibody-Drug Conjugates. <i>Topics in Medicinal Chemistry</i> , 2017, , 289-289.	0.4	1
657	Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. <i>Blood Cancer Journal</i> , 2017, 7, e603-e603.	2.8	161
658	Ligand-Targeted Drug Delivery. <i>Chemical Reviews</i> , 2017, 117, 12133-12164.	23.0	408
659	Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies. <i>Blood</i> , 2017, 130, 2018-2026.	0.6	23
660	Brentuximab vedotin in CD30 ⁺ cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. <i>British Journal of Dermatology</i> , 2017, 177, 1503-1509.	1.4	27
661	Brentuximab vedotin in CD30 ⁺ primary cutaneous T-cell lymphomas: a review and analysis of existing data. <i>International Journal of Dermatology</i> , 2017, 56, 1400-1405.	0.5	11
662	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2017, 102, 1931-1935.	1.7	11
663	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 75.	2.0	15

#	ARTICLE	IF	CITATIONS
665	New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling. <i>Scientific Reports</i> , 2017, 7, 15920.	1.6	25
666	A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. <i>AAPS Journal</i> , 2017, 19, 1436-1448.	2.2	17
667	Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 5635-5642.	1.5	67
668	CD30 Expression Is Rare in Myeloid Leukemia Cutis: A Study of 55 Cases and Implications for Routine Diagnostic Algorithms. <i>American Journal of Dermatopathology</i> , 2017, 39, 351-357.	0.3	3
669	The evolving role of targeted drugs in the treatment of Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 775-782.	1.0	6
670	Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies. , 2017, 170, 8-13.		11
671	CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2017, 60, 160-166.	1.1	11
672	Entwicklung Pyrrolobenzodiazepin(PBD)-haltiger Antikörper-Wirkstoff-Konjugate (ADCs) ausgehend von Anthramycin. <i>Angewandte Chemie</i> , 2017, 129, 474-502.	1.6	13
673	From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs). <i>Angewandte Chemie - International Edition</i> , 2017, 56, 462-488.	7.2	197
674	Non-Hodgkin Lymphoma. <i>Pediatric Oncology</i> , 2017, , 69-117.	0.5	2
675	Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab. <i>Blood Reviews</i> , 2017, 31, 23-35.	2.8	15
676	Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. <i>Clinical Cancer Research</i> , 2017, 23, 1156-1166.	3.2	275
677	Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 1167-1176.	3.2	77
678	Brentuximab vedotin is an effective therapy for CD30 ⁺ mycosis fungoides and cutaneous anaplastic large-cell lymphoma: what is the cost?. <i>British Journal of Dermatology</i> , 2017, 177, 1474-1475.	1.4	4
679	Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. <i>Nature Communications</i> , 2017, 8, 2166.	5.8	71
680	Engineering Antibodies as Drugs: Principles and Practice. <i>Molecular Biology</i> , 2017, 51, 772-781.	0.4	2
682	Brentuximab vedotin. an antibody-drug conjugate targeting CD30. <i>Drug Delivery System</i> , 2017, 32, 126-133.	0.0	0
683	Patient-derived antibody recognizes a unique CD43 epitope expressed on all AML and has antileukemia activity in mice. <i>Blood Advances</i> , 2017, 1, 1551-1564.	2.5	21

#	ARTICLE	IF	CITATIONS
684	Clinical and immunological responses after CD30-specific chimeric antigen receptorâ€“redirected lymphocytes. <i>Journal of Clinical Investigation</i> , 2017, 127, 3462-3471.	3.9	301
685	Clinical targeting recombinant immunotoxins for cancer therapy. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3645-3665.	1.0	33
686	A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2284.	1.8	19
687	Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. <i>Molecules</i> , 2017, 22, 1281.	1.7	135
688	Brentuximab vedotin: clinical updates and practical guidance. <i>Blood Research</i> , 2017, 52, 243.	0.5	36
689	Economic Evaluation of Brentuximab Vedotin for Persistent Hodgkin Lymphoma. <i>Current Oncology</i> , 2017, 24, 6-14.	0.9	7
690	Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?. <i>Frontiers in Immunology</i> , 2017, 8, 1245.	2.2	124
691	Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 463-476.	1.0	17
692	Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2265-2276.	2.0	80
693	CD30 Expression vs. Serum Soluble CD30 (sCD30) Level: Role in Prognosis and Treatment of Acute Myeloid Leukaemia. <i>Journal of Clinical & Cellular Immunology</i> , 2017, 08, .	1.5	0
694	Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules. <i>Gland Surgery</i> , 2017, 6, 169-184.	0.5	83
695	Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2017, Volume 7, 37-52.	1.2	6
696	Primary cutaneous lymphomas â€“ diagnostic and therapeutic guidelines of the Polish Dermatological Society. <i>Przegląd Dermatologiczny</i> , 2017, 3, 243-268.	0.0	2
698	ALCL: is it now a curable disease?. <i>Blood</i> , 2017, 130, 2691-2692.	0.6	4
699	Safety, tolerability, and preliminary activity of IMG529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. <i>Investigational New Drugs</i> , 2018, 36, 869-876.	1.2	33
700	Update on the Treatment of Anaplastic Large Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 135-141.	1.2	20
701	Current and emerging treatment options for a patient with a second relapse of Hodgkinâ€™s lymphoma. <i>Expert Review of Hematology</i> , 2018, 11, 293-300.	1.0	5
702	Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. <i>Blood</i> , 2018, 131, 1654-1665.	0.6	71

#	ARTICLE	IF	CITATIONS
703	Transplant strategies in relapsed/refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 1689-1697.	0.6	36
704	Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy. <i>Case Reports in Oncology</i> , 2018, 10, 795-801.	0.3	4
705	Hodgkin lymphoma: 2018 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2018, 93, 704-715.	2.0	109
706	Pathology of Non-Hodgkin and Hodgkin Lymphomas. , 2018, , 773-826.		0
707	Preparation and anti-cancer evaluation of promiximab-MMAE, an anti-CD56 antibody drug conjugate, in small cell lung cancer cell line xenograft models. <i>Journal of Drug Targeting</i> , 2018, 26, 905-912.	2.1	11
708	Frontline brentuximab vedotin in breast implant-associated anaplastic large cell lymphoma. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 634-637.	0.2	31
709	Trogocytosis of ligand-receptor complex and its intracellular transport in CD30 signalling. <i>Biology of the Cell</i> , 2018, 110, 109-124.	0.7	22
711	ABVD Without Radiation for Newly Diagnosed Pediatric and Young Adult Patients With Hodgkin Lymphoma: A Single Center Retrospective Analysis of 28 Consecutive Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 290-294.	0.3	9
712	MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding <i>In Vivo</i> Activity against HER2-Expressing Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 786-794.	1.9	17
713	Antibody-Drug Conjugates for Cancer Treatment. <i>Annual Review of Medicine</i> , 2018, 69, 191-207.	5.0	227
714	Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 989-999.	2.3	20
715	Anti-NaPi2b antibody-drug conjugate ifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. <i>Annals of Oncology</i> , 2018, 29, 917-923.	0.6	61
716	Pathogenesis of Peripheral T Cell Lymphoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 293-320.	9.6	36
717	CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. <i>Haematologica</i> , 2018, 103, 655-665.	1.7	24
718	A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma. <i>Haematologica</i> , 2018, 103, 840-848.	1.7	45
719	Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability. <i>Protein Engineering, Design and Selection</i> , 2018, 31, 47-54.	1.0	42
720	Precision Molecular Pathology of Hodgkin Lymphoma. <i>Molecular Pathology Library</i> , 2018, , .	0.1	2
721	Current Status of Immuno-Oncology in Hematologic Cancers. , 2018, , 641-655.		0

#	ARTICLE	IF	CITATIONS
722	Novel Targeted Therapies in Hodgkin Lymphoma. Molecular Pathology Library, 2018, , 221-230.	0.1	0
723	Brentuximab vedotin-induced peripheral neuropathy: looking at microtubules. Journal of Neuro-Oncology, 2018, 137, 665-666.	1.4	8
724	Monoclonal Antibodies Targeting Hematological Malignancies. , 2018, , 79-116.		0
725	Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Annals of Oncology, 2018, 29, 724-730.	0.6	44
726	Targeting the Microenvironment in Hodgkin Lymphoma: Opportunities and Challenges. Molecular Pathology Library, 2018, , 59-90.	0.1	0
728	Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol. BMC Cancer, 2018, 18, 122.	1.1	9
729	A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30 ⁺ lymphomas. Molecular Oncology, 2018, 12, 339-355.	2.1	23
730	Diagnosis and Treatment of Hodgkin Lymphoma. , 2018, , 903-937.		0
731	Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes. Pediatric Blood and Cancer, 2018, 65, e27094.	0.8	7
732	Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. Molecular Pharmaceutics, 2018, 15, 1627-1634.	2.3	19
734	Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review. Targeted Oncology, 2018, 13, 287-308.	1.7	12
735	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
736	NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 245-254.	2.3	45
737	Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein and Cell, 2018, 9, 33-46.	4.8	494
738	Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. , 2018, 181, 126-142.		97
739	Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy. Hematological Oncology, 2018, 36, 166-173.	0.8	26
740	Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). Oncoimmunology, 2018, 7, e1395127.	2.1	117
741	Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Investigational New Drugs, 2018, 36, 121-135.	1.2	157

#	ARTICLE	IF	CITATIONS
742	Brentuximab vedotin exerts profound antiproliferative and proapoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 568-575.	1.6	17
743	Chimeric antigen receptor T-cell therapies for lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 31-46.	12.5	391
744	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
745	Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned. <i>Clinical Pharmacokinetics</i> , 2018, 57, 687-703.	1.6	63
746	Progress in the Treatment of Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 392-394.	13.9	13
747	The target invites a foe: antibody-drug conjugates in gynecologic oncology. <i>Current Opinion in Obstetrics and Gynecology</i> , 2018, 30, 44-50.	0.9	15
748	Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab. <i>Current Problems in Dermatology</i> , 2018, 53, 70-81.	0.8	5
749	Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 1861-1870.	0.6	12
750	New developments in immunotherapy for pediatric solid tumors. <i>Current Opinion in Pediatrics</i> , 2018, 30, 30-39.	1.0	16
751	Endogenous Molecular-Cellular Network Cancer Theory: A Systems Biology Approach. <i>Methods in Molecular Biology</i> , 2018, 1702, 215-245.	0.4	5
752	Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin,) Tj ETQq0 0 0 rgBT /Overlock 10 863-870.	0.6	22
753	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 3298-3306.	0.8	88
754	The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered. <i>HemaSphere</i> , 2018, 2, e52.	1.2	3
755	Fully synthetic macromolecular prodrug chemotherapeutics with EGFR targeting and controlled camptothecin release kinetics. <i>Polymer Chemistry</i> , 2018, 9, 5224-5233.	1.9	13
756	CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis. <i>Oncotarget</i> , 2018, 9, 16547-16556.	0.8	16
757	Plasmablastic lymphoma: current perspectives. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2018, Volume 8, 63-70.	1.2	75
758	Chemoenzymatic Bioconjugation of Antibodies: Linking Proteins for Biomedical Applications. , 2018, , 359-381.		1
759	Enzymes in Food Technology. , 2018, , .		31

#	ARTICLE	IF	CITATIONS
760	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1641-1653.	5.1	193
761	Brentuximab vedotin for lymphoma in paediatric patients. <i>Lancet Haematology</i> ,the, 2018, 5, e433-e434.	2.2	0
762	2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory) Tj ETQq0 0 OogBT /Overlock 10 Tf		
763	Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. <i>Clinical Cancer Drugs</i> , 2018, 5, 42-49.	0.3	4
764	Novel therapeutic agents for relapsed classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 105-112.	1.2	16
765	Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 555-569.	1.2	6
766	Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. <i>Lancet Haematology</i> ,the, 2018, 5, e450-e461.	2.2	79
767	Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models. <i>Oncotarget</i> , 2018, 9, 5197-5207.	0.8	23
768	Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin. <i>British Journal of Haematology</i> , 2018, 183, 251-256.	1.2	10
769	Treatment of Relapsed Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S88-S90.	0.2	0
770	An overview of cancer immunotherapeutic strategies. <i>Immunotherapy</i> , 2018, 10, 999-1010.	1.0	26
771	Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. <i>British Journal of Haematology</i> , 2018, 183, 400-410.	1.2	18
772	Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. <i>Blood Advances</i> , 2018, 2, 821-824.	2.5	8
773	Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. <i>Annals of Hematology</i> , 2018, 97, 1301-1315.	0.8	6
774	Improving the Safety Profile of ADCs. <i>Cancer Drug Discovery and Development</i> , 2018, , 45-71.	0.2	1
775	Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads. <i>Advances in Protein Chemistry and Structural Biology</i> , 2018, 112, 143-182.	1.0	11
776	Aplysinopsins as Promising Marine Natural Product Drug Leads: Recent Developments. <i>Grand Challenges in Biology and Biotechnology</i> , 2018, , 191-215.	2.4	6
777	Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase. <i>Molecular Pharmaceutics</i> , 2018, 15, 3260-3271.	2.3	21

#	ARTICLE	IF	CITATIONS
778	Glutamic acidâ€“valineâ€“citrulline linkers ensure stability and efficacy of antibodyâ€“drug conjugates in mice. <i>Nature Communications</i> , 2018, 9, 2512.	5.8	119
780	Adnectinâ€“drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors. <i>Protein Engineering, Design and Selection</i> , 2018, 31, 159-171.	1.0	19
781	Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events. <i>Clinical Journal of Oncology Nursing</i> , 2018, 22, E103-E114.	0.3	5
782	Neurologic Complications of Systemic Anticancer Therapy. <i>Neurologic Clinics</i> , 2018, 36, 627-651.	0.8	5
783	Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4583-4590.	1.0	30
784	Molecular Targeted Therapy of Pediatric Neoplasms. <i>Molecular Pathology Library</i> , 2018, , 67-86.	0.1	0
785	Emerging Molecular Targets for Anti-Cancer Drug Design. <i>Current Chemical Biology</i> , 2018, 12, 88-99.	0.2	0
786	Malignant Lymphomas in Childhood. , 2018, , 1330-1342.e5.		2
787	Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. <i>Cancers</i> , 2018, 10, 99.	1.7	59
788	Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. <i>Frontiers in Immunology</i> , 2017, 8, 1936.	2.2	39
789	Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2018, 8, 193.	1.3	12
791	Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma. <i>Experimental Hematology and Oncology</i> , 2018, 7, 12.	2.0	42
792	Efficacy of antibodyâ€“drug conjugate brentuximab vedotin in treating Hodgkinâ€™s lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 841-849.	1.4	5
793	Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2265-2270.	2.0	10
794	Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 57.	6.9	19
795	Determining the sequence of novel therapies in the treatment of relapsed Hodgkinâ€™s lymphoma. <i>Expert Review of Hematology</i> , 2018, 11, 773-780.	1.0	1
796	Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers- an overview. <i>Journal of Drug Delivery Science and Technology</i> , 2018, 48, 106-117.	1.4	16
797	Update on the role of brentuximab vedotin in classical Hodgkin lymphoma. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 261-272.	1.1	6

#	ARTICLE	IF	CITATIONS
798	Precision Medicine in Head and Neck Cancer: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491877958.	0.6	18
799	Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. <i>Journal of Controlled Release</i> , 2018, 284, 49-56.	4.8	48
800	A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo. <i>PLoS ONE</i> , 2018, 13, e0191046.	1.1	19
801	Abdominal Pain and Intermittent Fevers in a 16-Year-Old Girl. <i>Pediatrics</i> , 2019, 144, .	1.0	1
802	High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 717.	1.3	18
803	Brief update on endocytosis of nanomedicines. <i>Advanced Drug Delivery Reviews</i> , 2019, 144, 90-111.	6.6	251
804	Targeting Biology in Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 727-738.	0.9	1
805	Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 823-829.	0.7	10
806	Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. <i>Cancers</i> , 2019, 11, 1071.	1.7	32
807	Peripheral T-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 657-668.	0.9	7
808	<i>DUSP22-IRF4</i> rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma. <i>BMJ Case Reports</i> , 2019, 12, e230641.	0.2	2
809	Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5503.	1.8	30
810	CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 113.	6.9	69
812	Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models. <i>Cancer Science</i> , 2019, 110, 3296-3305.	1.7	11
813	Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies. <i>European Journal of Cancer</i> , 2019, 120, 40-46.	1.3	19
814	Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 94.	6.9	70
815	Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase. <i>Molecules</i> , 2019, 24, 3287.	1.7	14
816	GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. <i>Cell Reports</i> , 2019, 28, 3367-3380.e8.	2.9	37

#	ARTICLE	IF	CITATIONS
817	Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. <i>Prostate</i> , 2019, 79, 604-613.	1.2	43
818	2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). <i>Aesthetic Surgery Journal</i> , 2019, 39, S3-S13.	0.9	231
819	Novel Agents in Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 45-53.	1.0	19
820	Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma. <i>International Journal of Hematology</i> , 2019, 109, 622-626.	0.7	5
821	Multiple Eruptive Dermatofibromas in a Patient Treated With Brentuximab Vedotin. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 417-418.	0.2	1
822	Principles of Immunotherapy. , 2019, , 295-304.		0
823	Novel Therapies in Paediatric NHL. , 2019, , 315-335.		0
824	Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	25
825	Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1268-1279.	2.3	12
826	Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management. <i>Histopathology</i> , 2019, 75, 787-796.	1.6	45
827	Pneumocystis jirovecii Pneumonia during Brentuximab Vedotin Therapy: A Case Report and Literature Review. <i>Case Reports in Hematology</i> , 2019, 2019, 1-3.	0.3	4
828	Brentuximab vedotin as monotherapy for unresectable breast implant-associated anaplastic large cell lymphoma. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1003-1006.	0.2	10
829	Upfront autologous hematopoietic stem cell transplantation in patients with high-risk stage III to IV Hodgkin lymphoma: a multicenter retrospective cohort study. <i>Hematology</i> , 2019, 24, 225-231.	0.7	2
830	Monoclonal Antibodies: From Structure to Therapeutic Application. , 2019, , 151-190.		0
831	Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. , 2019, 200, 110-125.		98
832	Treatment of classical Hodgkin's lymphoma in children and adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1227-1234.	0.9	7
833	Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma. <i>Cancer Research</i> , 2019, 79, 3395-3405.	0.4	39
834	Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates. <i>ChemBioChem</i> , 2019, 20, 2729-2737.	1.3	57

#	ARTICLE	IF	CITATIONS
835	Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy. <i>Cancers</i> , 2019, 11, 421.	1.7	8
836	Role of Fcγ3Rs in Antibody-Based Cancer Therapy. <i>Current Topics in Microbiology and Immunology</i> , 2019, 423, 13-34.	0.7	13
837	Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages. <i>Journal of Controlled Release</i> , 2019, 299, 107-120.	4.8	17
838	Dermatofibromas eruptivos múltiples en una paciente tratada con brentuximab vedotin. <i>Actas Dermo-sifilográficas</i> , 2019, 110, 419-420.	0.2	3
839	Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives. <i>British Journal of Haematology</i> , 2019, 185, 1021-1042.	1.2	37
840	Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 1142-1157.	1.2	29
841	Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 468-479.	1.2	17
842	A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2019, 37, 1052-1060.	1.2	11
843	Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 17.	2.8	35
844	Brentuximab vedotin in the treatment of CD30+ PTCL. <i>Blood</i> , 2019, 134, 2339-2345.	0.6	20
845	Immunotoxins: Targeted Toxin Delivery for Cancer Therapy. <i>Pharmaceutical Fronts</i> , 2019, 01, e33-e45.	0.4	16
846	<p></p>The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 63-71.	1.2	11
847	Burden of lymphoma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016. <i>Journal of Hematology and Oncology</i> , 2019, 12, 115.	6.9	56
848	Cancer biomarkers for targeted therapy. <i>Biomarker Research</i> , 2019, 7, 25.	2.8	72
849	ADCs on the Market and in Clinical Development. , 2019, , 155-174.		2
851	T-Cell and NK-Cell Lymphomas. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	0
852	Transplantation. <i>Cancer Treatment and Research</i> , 2019, 176, 269-287.	0.2	2
853	CD30-positive cutaneous extranodal natural killer/T-cell lymphoma: clinicopathological features and survival outcomes. <i>International Journal of Dermatology</i> , 2019, 58, 688-696.	0.5	4

#	ARTICLE	IF	CITATIONS
854	Clinical Evaluation and Management of Hodgkin Lymphoma. , 2019, , 371-378.		2
855	Hydrophilic Monomethyl Auristatin E Derivatives as Novel Candidates for the Design of Antibody-Drug Conjugates. Separations, 2019, 6, 1.	1.1	20
856	Safety and Tolerability of Antibody-Drug Conjugates in Cancer. Drug Safety, 2019, 42, 295-314.	1.4	75
857	Advances in cellular and humoral immunotherapy â€” implications for the treatment of poor risk childhood, adolescent, and young adult Bâ€cell nonâ€Hodgkin lymphoma. British Journal of Haematology, 2019, 185, 1055-1070.	1.2	16
858	CARâ€T cells beyond CD19, UnCARâ€ed territory. American Journal of Hematology, 2019, 94, S34-S41.	2.0	6
859	Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3KÎ³/Î² Inhibitor RP6530. Clinical Cancer Research, 2019, 25, 1098-1112.	3.2	69
860	Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study. Haematologica, 2019, 104, e151-e153.	1.7	27
861	A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 studyâ€. Leukemia and Lymphoma, 2019, 60, 912-919.	0.6	18
862	Brentuximab vedotin in T-cell lymphoma. Expert Review of Hematology, 2019, 12, 5-19.	1.0	18
863	Chimeric Antigen Receptor T Cells for Lymphomas: Methods, Data, and Challenges. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy, 2019, , 93-108.	0.0	0
865	Antibody-Drug Conjugates. Methods in Molecular Biology, 2020, , .	0.4	7
866	Folate-conjugated nanovehicles: Strategies for cancer therapy. Materials Science and Engineering C, 2020, 107, 110341.	3.8	64
867	Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment. Bone Marrow Transplantation, 2020, 55, 117-125.	1.3	12
868	Mature lymphoid neoplasms. , 2020, , 603-625.		0
869	Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study. Leukemia and Lymphoma, 2020, 61, 176-180.	0.6	14
870	Neurotoxicity of antibodies in cancer therapy: A review. Clinical Neurology and Neurosurgery, 2020, 188, 105566.	0.6	8
871	Poikilodermatous mycosis fungoides with CD30â€positive large cell transformation successfully treated by brentuximab vedotin. Dermatologic Therapy, 2020, 33, e13152.	0.8	2
872	Antibodyâ€Drug Conjugates: A Comprehensive Review. Molecular Cancer Research, 2020, 18, 3-19.	1.5	442

#	ARTICLE	IF	CITATIONS
873	Brentuximab a novel antibody therapy: real-world use confirms efficacy and tolerability for CD30-positive cutaneous lymphoma. <i>British Journal of Dermatology</i> , 2020, 182, 799-800.	1.4	12
874	Lymphomatoid papulosis: an update and review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 59-73.	1.3	42
875	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma. <i>Annals of Hematology</i> , 2020, 99, 255-264.	0.8	3
876	A phase I study of the antibody-drug conjugate brentuximab vedotin with induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 1264-1273.	2.0	15
877	Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma—a long-term follow-up single center experience. <i>Annals of Hematology</i> , 2020, 99, 265-276.	0.8	3
878	Neurologic Complications. , 2020, , 688-706.e7.		1
879	Childhood Lymphoma. , 2020, , 1765-1782.e7.		0
880	Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. <i>American Journal of Surgical Pathology</i> , 2020, 44, e1-e14.	2.1	13
881	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-10. Hodgkin lymphoma (HL). <i>International Journal of Hematology</i> , 2020, 111, 166-179.	0.7	4
882	Clinicopathologic features and prognostic significance of CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. <i>Biomarkers</i> , 2020, 25, 69-75.	0.9	14
883	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 684-693.	0.6	126
884	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5579-5587.	3.2	16
885	An antibody-drug conjugate targeting a GSTA glycosite signature epitope of MUC1 expressed by non-small cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 9529-9540.	1.3	9
886	Tumor Therapeutic Modes. , 2020, , 135-229.		1
887	Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells. <i>PLoS ONE</i> , 2020, 15, e0239813.	1.1	9
888	Basic research in childhood cancer: Progress and future directions in China. <i>Cancer Letters</i> , 2020, 495, 156-164.	3.2	11
889	COBRA ₂ : a highly potent conditionally active T cell engager engineered for the treatment of solid tumors. <i>MAbs</i> , 2020, 12, 1792130.	2.6	30
890	Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma. <i>Future Oncology</i> , 2020, 16, 2273-2282.	1.1	8

#	ARTICLE	IF	CITATIONS
891	Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model-Informed Hypothesis Generation for Pediatric Dosing Regimens. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1585-1597.	1.0	3
892	Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody. <i>Clinical and Translational Immunology</i> , 2020, 9, e1156.	1.7	3
893	Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates. <i>AAPS Journal</i> , 2020, 22, 105.	2.2	12
894	Monoclonal Antibodies in Cancer Therapy. <i>Antibodies</i> , 2020, 9, 34.	1.2	325
895	CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma. <i>British Journal of Cancer</i> , 2020, 123, 1101-1113.	2.9	17
896	Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non-Hodgkin lymphoma. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 100, 488-496.	0.7	4
897	Hodgkin lymphoma: outsmarting HRS cells. <i>Blood</i> , 2020, 136, 2362-2364.	0.6	10
898	Advances in CAR T Therapy for Hematologic Malignancies. <i>Pharmacotherapy</i> , 2020, 40, 741-755.	1.2	11
899	Improved targeting of an anti-CTAG1 antibody drug conjugate for the treatment of ovarian cancer. <i>Cancer Medicine</i> , 2020, 9, 4756-4767.	1.3	12
900	Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 831-839.	1.4	9
901	The emerging role of antibody-drug conjugates in urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 551-561.	1.1	23
902	Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges. <i>Frontiers in Pharmacology</i> , 2020, 11, 997.	1.6	56
903	Advances in targeted therapy for malignant lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 15.	7.1	66
904	DNA Origami-Enabled Engineering of Ligand-Drug Conjugates for Targeted Drug Delivery. <i>Small</i> , 2020, 16, e1904857.	5.2	58
905	Immune-Based Approaches for the Treatment of Pediatric Malignancies. <i>Annual Review of Cancer Biology</i> , 2020, 4, 353-370.	2.3	7
906	Metabolomic study of soft corals from the Colombian Caribbean: PSYCHE and 1H-NMR comparative analysis. <i>Scientific Reports</i> , 2020, 10, 5417.	1.6	17
907	Aptamer-Equipped Protamine Nanomedicine for Precision Lymphoma Therapy. <i>Cancers</i> , 2020, 12, 780.	1.7	16
908	<p>Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5993-6009.	1.0	9

#	ARTICLE	IF	CITATIONS
909	Harnessing immunotherapy for pediatric T-cell malignancies. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 361-371.	1.3	12
910	Systematic identification of engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 5733-5740.	3.3	35
911	Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1732-1735.	0.6	5
912	Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 157-167.	1.9	21
913	Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients. <i>Blood Cancer Journal</i> , 2020, 10, 8.	2.8	32
914	Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma. <i>International Journal of Hematology</i> , 2020, 111, 711-718.	0.7	6
915	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers. <i>European Journal of Cancer</i> , 2020, 128, 107-118.	1.3	36
916	Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 9-19.	1.2	25
917	Recent advances of antibody drug conjugates for clinical applications. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1589-1600.	5.7	102
918	Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. <i>Biomaterials</i> , 2020, 248, 120032.	5.7	14
919	In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1337-1352.	2.0	15
920	Aptamer technology: a new approach to treat lymphoma?. <i>Blood Science</i> , 2020, 2, 11-15.	0.4	3
921	Kinetic and structural characterization of therapeutic albumin chemical functionalization using complementary mass spectrometry techniques. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 185, 113242.	1.4	4
922	Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 871-885.	1.4	57
923	⁹⁰Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 249-261.	0.7	9
924	Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , 2021, 106, 1129-1137.	1.7	57
925	Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. <i>Haematologica</i> , 2021, 106, 1705-1713.	1.7	34
926	Targeted Engineering of Medicinal Chemistry for Cancer Therapy: Recent Advances and Perspectives. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 5626-5643.	7.2	47

#	ARTICLE	IF	CITATIONS
927	Zielgerichtete Wirkstoffe für die Krebstherapie: Aktuelle Entwicklungen und Perspektiven. <i>Angewandte Chemie</i> , 2021, 133, 5686-5705.	1.6	3
928	Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation. <i>Journal of Controlled Release</i> , 2021, 329, 676-695.	4.8	111
929	Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 70-77.	0.6	6
930	Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). <i>British Journal of Haematology</i> , 2021, 193, 63-71.	1.2	19
931	A review of CD30 expression in cutaneous neoplasms. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 495-510.	0.7	12
932	A Reagent for Amine-Directed Conjugation to IgG1 Antibodies. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 6539-6544.	7.2	21
933	Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains. <i>Human Gene Therapy</i> , 2021, 32, 730-743.	1.4	9
934	Exploring the Diversity of the Marine Environment for New Anti-cancer Compounds. <i>Frontiers in Marine Science</i> , 2021, 7, .	1.2	22
935	A Reagent for Amine-Directed Conjugation to IgG1 Antibodies. <i>Angewandte Chemie</i> , 2021, 133, 6613-6618.	1.6	8
936	Relapse After Hematopoietic Cell Transplantation. , 2021, , 711-721.		0
937	Morbus Hodgkin. <i>Springer Reference Medizin</i> , 2021, , 1-12.	0.0	0
938	N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability. <i>MAbs</i> , 2021, 13, 1914885.	2.6	3
939	A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate. <i>Theranostics</i> , 2021, 11, 2550-2563.	4.6	15
940	Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. <i>RSC Chemical Biology</i> , 2021, 2, 1206-1220.	2.0	15
941	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment. <i>The Korean Journal of Urological Oncology</i> , 2021, 19, 30-39.	0.1	0
942	AYA Considerations for Aggressive Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 61-71.	1.2	1
943	From antibodies to living drugs: Quo vadis cancer immunotherapy?. <i>Biologia Futura</i> , 2021, 72, 85-99.	0.6	2
944	Extracellular vesicles as modifiers of antibody-drug conjugate efficacy. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12070.	5.5	17

#	ARTICLE	IF	CITATIONS
945	Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma. <i>Life Sciences</i> , 2021, 268, 118979.	2.0	4
946	Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers. <i>Frontiers in Chemistry</i> , 2021, 9, 613209.	1.8	9
947	Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin. <i>Molecular and Clinical Oncology</i> , 2021, 14, 121.	0.4	3
948	Antibody–drug conjugates: Recent advances in linker chemistry. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3889-3907.	5.7	114
949	Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin. <i>Seminars in Hematology</i> , 2021, 58, 85-94.	1.8	4
950	Comment on “Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.” <i>Haematologica</i> , 2021, 106, 1226-1227.	1.7	0
951	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2021, 22, 512-524.	5.1	144
952	Risk Minimization of Antibody–Drug Conjugates in Oncology: A Review. <i>Drug Safety</i> , 2021, 44, 733-742.	1.4	6
953	An Unusual Hodgkin's Lymphoma Journey: Cardiac Tamponade, Primary Refractoriness, Immune Thrombocytopenia, and Post-Traumatic Stress Disorder. <i>Cureus</i> , 2021, 13, e15341.	0.2	0
954	Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma—A Single Center Experience. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 290-298.	0.3	1
955	The Expanding Role of Chemistry in Optimizing Proteins for Human Health Applications. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7179-7188.	2.9	8
956	Primary bone anaplastic lymphoma kinase positive anaplastic large-cell lymphoma: A case report and review of the literature. <i>World Journal of Clinical Cases</i> , 2021, 9, 3403-3410.	0.3	2
957	Immunotherapy for Breast Cancer Treatment. <i>Iranian Biomedical Journal</i> , 2021, 25, 140-156.	0.4	2
958	Primary cutaneous T-cell lymphomas other than mycosis fungoides and S�azary syndrome. Part II: Prognosis and management. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1093-1106.	0.6	8
959	Breast implant-associated anaplastic large-cell lymphoma: a European case report and literature review. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	1
960	Barriers to antibody therapy in solid tumors, and their solutions. <i>Cancer Science</i> , 2021, 112, 2939-2947.	1.7	13
961	Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials. <i>JCO Precision Oncology</i> , 2021, 5, 1024-1034.	1.5	2
962	Immunotherapy in the treatment of lymphoma. <i>World Journal of Stem Cells</i> , 2021, 13, 503-520.	1.3	3

#	ARTICLE	IF	CITATIONS
963	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	0.8	32
964	Advancements in folate receptor targeting for anti-cancer therapy: A small molecule-drug conjugate approach. <i>Bioorganic Chemistry</i> , 2021, 112, 104946.	2.0	33
965	Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1216-1230.	2.3	25
966	Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer. <i>BMC Cancer</i> , 2021, 21, 777.	1.1	3
967	How to Sequence Therapies in Peripheral T Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 74.	1.3	4
968	Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL). <i>Yeungnam University Journal of Medicine</i> , 2021, 38, 175-182.	0.7	10
969	A Wireframe DNA Cube: Antibody Conjugate for Targeted Delivery of Multiple Copies of Monomethyl Auristatin...E. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 21691-21696.	7.2	21
970	Current Insights and Advancements in Head and Neck Cancer: Emerging Biomarkers and Therapeutics with Cues from Single Cell and 3D Model Omics Profiling. <i>Frontiers in Oncology</i> , 2021, 11, 676948.	1.3	5
971	Integrated Medicine for Chemotherapy-Induced Peripheral Neuropathy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9257.	1.8	7
972	A Wireframe DNA Cube: Antibody Conjugate for Targeted Delivery of Multiple Copies of Monomethyl Auristatin...E. <i>Angewandte Chemie</i> , 2021, 133, 21859-21864.	1.6	0
973	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5781-5792.	3.2	30
974	Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2228-2239.	1.9	8
975	The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. <i>Cancers</i> , 2021, 13, 4701.	1.7	6
976	Non-Genetic Generation of Antibody Conjugates Based on Chemoenzymatic Tyrosine Click Chemistry. <i>Bioconjugate Chemistry</i> , 2021, 32, 2167-2172.	1.8	10
977	Polymeric nanomedicines targeting hematological malignancies. <i>Journal of Controlled Release</i> , 2021, 337, 571-588.	4.8	15
978	Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model. <i>Biomacromolecules</i> , 2021, 22, 4169-4180.	2.6	7
979	An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. <i>Molecules</i> , 2021, 26, 5847.	1.7	158
980	Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate. <i>Leukemia and Lymphoma</i> , 2022, 63, 239-242.	0.6	5

#	ARTICLE	IF	CITATIONS
981	T time: Emerging and new therapies for peripheral T-cell lymphoma. Blood Reviews, 2022, 52, 100889.	2.8	6
982	How I treat neurologic complications in patients with lymphoid cancer. Blood, 2022, 139, 1469-1478.	0.6	2
983	Immunotherapy in hematological malignancies: recent advances and open questions. Immunotherapy, 2021, 13, 1215-1229.	1.0	11
984	Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress. Journal of Clinical Oncology, 2021, 39, 3097-3103.	0.8	4
985	PSMA-targeted low-molecular double conjugates for diagnostics and therapy. European Journal of Medicinal Chemistry, 2021, 225, 113752.	2.6	8
986	Neurological Complications. , 2021, , 593-622.		0
988	AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+â€%ALCL. Experimental Hematology and Oncology, 2021, 10, 4.	2.0	40
989	Approach to chemotherapy-induced peripheral neuropathy. , 2021, , 356-370.		0
990	From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs). Angewandte Chemie - International Edition, 2017, 56, 462-488.	7.2	2
993	Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins. , 2013, , 3-22.		3
994	Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer. , 2013, , 179-210.		1
995	Case Study: An Antibodyâ€“Drug Conjugate Targeting MUC16 for Ovarian Cancer. , 2013, , 221-239.		1
996	Antibodyâ€“Drug Conjugate Development. , 2013, , 23-38.		2
997	Predictive Biomarkers for Antibodyâ€“Drug Conjugates. , 2013, , 77-90.		2
998	Monoclonal Antibodies: From Structure to Therapeutic Application. , 2013, , 143-178.		5
999	Unnatural Amino Acid Antibody Conjugates as Next Generation Biologics. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 167-181.	0.1	3
1000	Determination of ADC Cytotoxicity in Immortalized Human Cell Lines. Methods in Molecular Biology, 2020, 2078, 329-340.	0.4	8
1001	Monoclonal Antibodies for Lymphoma. , 2013, , 345-361.		1

#	ARTICLE	IF	CITATIONS
1002	Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates. <i>Methods in Molecular Biology</i> , 2013, 1045, 117-131.	0.4	17
1003	Leukämien und Lymphome. , 2018, , 267-357.		1
1004	Monoclonal Antibodies for Cancer Therapy. , 2014, , 2911-2919.		1
1005	Antibody Therapies in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 1-67.	0.8	8
1006	Childhood Lymphoma. , 2014, , 1873-1889.e6.		3
1007	Non-Hodgkin Lymphoma. , 2014, , 2033-2059.e8.		1
1009	Maleimide-thiol adducts stabilized through stretching. <i>Nature Chemistry</i> , 2019, 11, 310-319.	6.6	154
1010	Auristatin Payloads for Antibody-Drug Conjugates (ADCs). <i>RSC Drug Discovery Series</i> , 2019, , 73-99.	0.2	3
1012	Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors. <i>Cancer Research</i> , 2021, 81, 763-775.	0.4	13
1013	Immunotherapy of lymphomas. <i>Journal of Clinical Investigation</i> , 2020, 130, 1576-1585.	3.9	32
1014	New molecular insights into peripheral T cell lymphomas. <i>Journal of Clinical Investigation</i> , 2012, 122, 3448-3455.	3.9	35
1015	Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. <i>Drugs of Today</i> , 2019, 55, 575.	0.7	30
1016	Increased Bone Marrow (BM) Plasma Level of Soluble CD30 and Correlations with BM Plasma Level of Interferon (IFN)- γ , CD4/CD8 T-Cell Ratio and Disease Severity in Aplastic Anemia. <i>PLoS ONE</i> , 2014, 9, e110787.	1.1	17
1017	Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e354-e366.	1.8	6
1018	Antibody-Drug Conjugates in Hematologic Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e108-e113.	1.8	3
1019	Novel Formulations and New Mechanisms of Delivering Chemotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e381-e386.	1.8	1
1020	Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report. <i>Journal of Hematology (Brossard, Quebec)</i> , 2019, 8, 132-136.	0.4	4
1021	Treatment of Hodgkin Lymphoma - New and Developing Therapies and Their Potential Role in Standard of Care. <i>European Oncology and Haematology</i> , 2019, 15, 53.	0.0	1

#	ARTICLE	IF	CITATIONS
1022	A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma. Sultan Qaboos University Medical Journal, 2015, 15, e317-321.	0.3	13
1023	Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience, 2015, 2, 576-580.	0.9	42
1024	The heterogeneous landscape of ALK negative ALCL. Oncotarget, 2017, 8, 18525-18536.	0.8	28
1025	Diverse Targeted Approaches to Battle Multidrug Resistance in Cancer. Current Medicinal Chemistry, 2019, 26, 7059-7080.	1.2	22
1026	ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies. Current Drug Delivery, 2020, 17, 23-51.	0.8	16
1027	Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 603-631.	0.9	39
1028	CEACAM1 is a Privileged Cell Surface Antigen to Design Novel ScFv Mediated-Immunotherapies of Melanoma, Lung Cancer and Other Types of Tumors. The Open Pharmacology Journal, 2012, 6, 1-11.	0.4	3
1029	Monoclonal Antibodies: Application in Radiopharmacy. Current Radiopharmaceuticals, 2014, 6, 231-248.	0.3	7
1030	Advantages of Drug Selective Distribution in Cancer Treatment: Brentuximab Vedotin. International Journal of Pharmacology, 2017, 13, 785-807.	0.1	3
1031	Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 120-142.	0.3	72
1032	Novel molecular multilevel targeted antitumor agents. Cancer Translational Medicine, 2017, 3, 69.	0.2	11
1033	Drug Combinations in Cancer Treatments. Clinical & Experimental Pharmacology, 2013, 03, .	0.3	6
1034	Liquid Biopsy in Liquid Tumors. Journal of Cancer Therapy, 2017, 08, 302-320.	0.1	5
1035	The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin. Annali Dell'Istituto Superiore Di Sanita, 2013, 49, 150-68.	0.2	17
1036	A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin. Chinese Journal of Cancer, 2013, 32, 520-523.	4.9	5
1037	Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 755-781.	2.3	94
1038	Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biology and Medicine, 2014, 11, 20-33.	1.4	109
1039	Hodgkin Lymphoma: A Special Microenvironment. Journal of Clinical Medicine, 2021, 10, 4665.	1.0	11

#	ARTICLE	IF	CITATIONS
1040	Adoptive T-cell therapy for Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 4291-4302.	2.5	11
1041	Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. <i>Current Problems in Cancer</i> , 2021, 45, 100794.	1.0	4
1042	Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103496.	2.0	4
1044	Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology. , 2012, , 183-240.		0
1045	Hodgkin's Lymphoma. , 2012, , 1527-1543.		1
1046	Hodgkin Lymphoma: From Molecular Pathogenesis to Targeted Therapy. , 2012, , 181-202.		0
1047	Kapitel E1 Literaturverzeichnis zu Peter, Pichler, MÃ¼ller-Ladner (Hrsg.): <i>Klinische Immunologie</i> . , 2012, , e1-e80.		0
1049	Individualized Cancer Chemotherapy by Detecting Cancer Biomarkers. <i>Metabolomics: Open Access</i> , 2012, 02, .	0.1	4
1050	Hodgkin's Lymphoma: From Tumor Microenvironment to Immunotherapeutic Approach - Body's Own Power Protection Challenges. , 0, , .		0
1051	Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma. , 0, , .		0
1052	Therapy for Relapsed and Refractory Pediatric Hodgkin Lymphoma. , 0, , .		0
1053	Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2012, 3, 184-90.	0.2	2
1054	Targeted Toxins in Cancer Immunotherapy. , 2013, , 377-396.		0
1055	Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates. , 2013, , 57-75.		0
1056	Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies. , 2013, , 161-175.		0
1057	Studies on the Metabolism of Antibody-Drug Conjugates. , 2013, , 297-316.		1
1058	Current Therapies for T-cell Lymphomas. , 2013, , 213-237.		0
1059	Monoclonal Antibodies in Cancer. , 2013, , 337-359.		1

#	ARTICLE	IF	CITATIONS
1060	Autres traitements pour le lymphome hodgkinien (LH) après la première rechute. , 2013, , 55-61.		0
1061	Neue Arzneimittel 2012. , 2013, , 47-120.		1
1062	Lymphoproliférations cutanées CD30+: lymphome cutané primitif à grandes cellules T CD30+ et papulose lymphomatoïde. , 2013, , 95-110.		0
1063	The World Health Organization Classification of Lymphoid Neoplasms. , 2013, , 1-34.		0
1064	Recent New Drug Approvals, Part 2: Drugs Undergoing Active Clinical Studies in Children. Journal of Pediatric Pharmacology and Therapeutics, 2013, 18, 14-38.	0.3	7
1065	Resistance to Anticancer Antibodies: From Mechanisms to Solutions. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 1-24.	0.1	0
1066	Molecular Profiling of Peripheral T-Cell Lymphomas. , 2013, , 53-63.		0
1067	Lymphome. , 2014, , 1519-1525.		0
1068	Lymphoma, Non-Hodgkinien. , 2014, , .		0
1069	Hodgkin-Lymphom. , 2014, , 503-506.		0
1070	Adult T-Cell Leukemia-Lymphoma. , 2014, , 2076-2092.e4.		0
1071	Anaplastic Large Cell Lymphoma. , 2014, , 111-120.		0
1072	Monoclonal Antibodies for Cancer Therapy. , 2014, , 1-9.		0
1073	Personalized Cancer Therapy: A Perspective. Clinical & Experimental Pharmacology, 2014, 04, .	0.3	2
1075	Antibody Drug Conjugates: A Leap Ahead in Cancer Treatment. Journal of Drug Delivery and Therapeutics, 2014, 4, .	0.2	1
1077	Targeting CD30 in Patients with Hodgkin Lymphoma. Hematologic Malignancies, 2015, , 343-354.	0.2	0
1078	What Will We Learn from Genomics and Proteomics in Hodgkin Lymphoma?. Hematologic Malignancies, 2015, , 79-92.	0.2	0
1081	Brentuximab Vedotin and Diffuse Large B-cell Lymphoma. Journal of Hematology & Thromboembolic Diseases, 2015, 03, .	0.1	0

#	ARTICLE	IF	CITATIONS
1082	Managing advanced stage Hodgkin lymphoma. Journal of Postgraduate Medicine, 2015, 61, 75-76.	0.2	0
1087	Classical Hodgkin's Lymphoma: Pathogenesis and Future Treatment Directions. Res Medica, 2015, 23, 48.	0.1	0
1089	Treatment of Hodgkin lymphoma. , 2016, , 83-93.		1
1090	Advances in Immunotherapy for Hematological Malignancies. Journal of the Nihon University Medical Association, 2016, 75, 167-170.	0.0	0
1091	Modern Aspects of Diagnosis and Treatment of Anaplastic Large Cell Lymphoma in Children (Literature) Tj ETQq0 0.0,rgBT /Oyerlock 10	0.1	2
1092	PET Response-Adapted Treatment in Hodgkin Lymphoma. , 2016, , 31-64.		0
1093	A Case of an Unusually Aggressive Cutaneous Anaplastic Large T-Cell Lymphoma in a Young Patient. International Journal of Cancer Studies & Research, 0, , 111-114.	0.0	0
1095	Overview of lymphoma. , 2017, , 1-9.		0
1097	Hodgkin lymphoma in elderly patients. Onkologie (Czech Republic), 2017, 11, 121-126.	0.0	0
1098	Antibody-Drug Conjugates in Head and Neck Cancer. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2017, 60, 331-335.	0.0	0
1099	Treatment and Prognosis. Molecular Pathology Library, 2018, , 197-219.	0.1	0
1100	Brentuximab Vedotin Infusion Reaction Management: A Case Study. Journal of the Advanced Practitioner in Oncology, 2017, 8, .	0.2	1
1101	Hodgkin-Lymphom bei Kindern und Jugendlichen. Springer Reference Medizin, 2018, , 1-9.	0.0	0
1102	Pacifastin-derived Peptides Target Tumors for Use in In Vivo Imaging. Anticancer Research, 2018, 38, 51-60.	0.5	0
1103	Recent Advances in Therapeutics for B-Cell Lymphoma. Journal of Pharmacy and Pharmacology, 2018, 6, .	0.1	0
1104	An update on antibody drug conjugates. Pharmacy & Pharmacology International Journal, 2018, 6, .	0.1	0
1105	Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma. Meditsinskiy Sovet, 2018, , 101-105.	0.1	0
1106	Successful experience in treating primary cutaneous anaplastic large cell lymphoma ocuring with common lesions of the skin and lung tissue. Vestnik Dermatologii i Venerologii, 2018, 94, 30-42.	0.2	0

#	ARTICLE	IF	CITATIONS
1107	Hodgkin Lymphoma: Revisited. , 2019, , 247-264.		0
1108	Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma. , 2019, , 231-243.		0
1109	Present and Future in Treatment of Hodgkin Lymphoma. Medicina Interna (Bucharest, Romania: 1991), 2019, 16, 33-39.	0.1	0
1110	The Current Status of Cancer Drug Delivery Systems and Future Directions. , 2019, , 311-319.		0
1111	Hodgkin-Lymphom bei Kindern und Jugendlichen. Springer Reference Medizin, 2019, , 815-823.	0.0	0
1112	Lymphome bei Kindern und Jugendlichen. Springer Reference Medizin, 2019, , 1-9.	0.0	0
1113	Overcoming Resistance in Relapsed Anaplastic Large-Cell Lymphoma, ALK-Positive (Literature Review) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.2	0
1114	Hypertriglyceridemia Induced Pancreatitis Due to Brentuximab Therapy: First Case Report. Cureus, 2019, 11, e5138.	0.2	3
1115	Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas. , 2020, , 27-46.		0
1116	Neurological Complications of Targeted Therapies. , 2020, , 341-363.		0
1118	Therapeutic response in patients with CD30+ lymphomas to biological therapy. Medicinski Podmladak, 2020, 71, 63-68.	0.2	0
1119	AJICAPâ,ç: Development of a Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugates. Yuki Gosei Kagaku Kyokaiishi/Journal of Synthetic Organic Chemistry, 2020, 78, 495-502.	0.0	0
1121	Chapter 2: Challenges and Considerations in the Design of Antibody-Drug Conjugates. AAPS Advances in the Pharmaceutical Sciences Series, 2020, , 27-48.	0.2	0
1123	Nanotechnology in Medicine. Ecoproduction, 2020, , 57-64.	0.8	2
1124	Adult T-Cell Leukemia/Lymphoma. , 2020, , 137-164.		0
1125	Targeting CD30 in Patients with Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 381-393.	0.2	0
1126	Immunopathology and Immunotherapy of Hodgkin Lymphoma. , 2020, , 135-157.		0
1127	Breast implant-associated anaplastic large cell lymphoma. Plastic Surgery and Aesthetic Medicine, 2020, , 5.	0.1	3

#	ARTICLE	IF	CITATIONS
1128	Lymphome. Springer Reference Medizin, 2020, , 2239-2247.	0.0	0
1129	Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 15716-15726.	2.9	35
1130	Novel Ion Channel Targets and Drug Delivery Tools for Controlling Glioblastoma Cell Invasiveness. International Journal of Molecular Sciences, 2021, 22, 11909.	1.8	7
1131	A CD205-directed antibody drug conjugate - lymphoma precision oncology or sophisticated chemotherapy?. Haematologica, 2020, 105, 2504-2506.	1.7	0
1132	Extranodal natural killer/T cell lymphoma: we should and we can do more. Chinese Clinical Oncology, 2015, 4, 12.	0.4	12
1134	Monoclonal antibodies in cancer therapy. Cancer Immunity, 2012, 12, 14.	3.2	206
1135	The era of personalized medicine in oncology: novel biomarkers ushering in new approaches to cancer therapy. American Health and Drug Benefits, 2011, 4, 387-8.	0.5	1
1136	A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphoma. Sultan Qaboos University Medical Journal, 2015, 15, e202-6.	0.3	2
1137	Hodgkin's lymphoma (relapsed or refractory): autologous stem cell therapy. Clinical Evidence, 2015, 2015, .	0.2	0
1139	Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). Discovery Medicine, 2017, 23, 189-199.	0.5	14
1140	Brentuximab Vedotin Infusion Reaction Management: A Case Study. Journal of the Advanced Practitioner in Oncology, 2017, 8, 626-629.	0.2	1
1141	Present and Future in Treatment of Hodgkin Lymphoma. Mădica, 2019, 14, 144-147.	0.4	0
1142	ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. Oncology, 2016, 30, 1099-103, 1106-8.	0.4	2
1143	Advanced Stage Hodgkin Lymphoma: Patient Management. Acta Biomedica, 2020, 91, 5-12.	0.2	0
1144	Beyond CD19 CAR-T cells in lymphoma. Current Opinion in Immunology, 2022, 74, 46-52.	2.4	3
1146	Introduction to Antibody-Drug Conjugates. RSC Drug Discovery Series, 2021, , 1-31.	0.2	2
1147	Hodgkin-Lymphom: Zielgerichtete Substanzen optimieren die Therapie. , 0, , .		0
1148	Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention. Journal of Oncology, 2022, 2022, 1-12.	0.6	1

#	ARTICLE	IF	CITATIONS
1149	Guttate psoriasis in a patient with mycosis fungoides in treatment with Brentuximab vedotin: An unreported association. <i>Dermatologic Therapy</i> , 2022, , e15309.	0.8	1
1150	Current salvage therapies in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1267-1280.	0.6	5
1151	CD30-targeted therapy induces apoptosis of inflammatory cytokine-stimulated synovial fibroblasts and ameliorates collagen antibody-induced arthritis in mice. <i>Inflammation Research</i> , 2022, 71, 215-226.	1.6	1
1152	Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. <i>Antibody Therapeutics</i> , 2022, 5, 18-29.	1.2	8
1153	Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29557.	0.8	5
1154	Safety considerations with the current treatments for peripheral T-cell lymphoma. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 653-660.	1.0	1
1155	Emerging new therapeutic antibody derivatives for cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 39.	7.1	158
1156	Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. <i>Pharmaceutics</i> , 2022, 14, 396.	2.0	48
1157	The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkinâ€™s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2022, 15, 42-53.	0.1	0
1158	Affinity-Guided Site-Selective Labeling of Nanobodies with Aldehyde Handles. <i>Methods in Molecular Biology</i> , 2022, 2446, 345-356.	0.4	0
1159	Antibody-drug Conjugate Targets, Drugs, and Linkers. <i>Current Cancer Drug Targets</i> , 2022, 22, 463-529.	0.8	9
1160	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. <i>Cancers</i> , 2022, 14, 1253.	1.7	69
1161	Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas. <i>Journal of Personalized Medicine</i> , 2022, 12, 267.	1.1	4
1162	Aggressive Primary Cutaneous Anaplastic T-Cell Lymphoma Successfully Treated with Autologous Stem Cell Transplant and Brentuximab Vedotin Consolidation: Case Report and Review of the Literature. <i>Hematology Reports</i> , 2022, 14, 61-66.	0.3	1
1163	Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage. <i>Cancers</i> , 2022, 14, 1540.	1.7	11
1164	Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 145-151.	0.6	4
1165	FDA-Approved Drugs for Hematological Malignanciesâ€™The Last Decade Review. <i>Cancers</i> , 2022, 14, 87.	1.7	38
1166	Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy. <i>Cancers</i> , 2021, 13, 6125.	1.7	11

#	ARTICLE	IF	CITATIONS
1167	Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?. Exploration of Targeted Anti-tumor Therapy, 0, , 149-171.	0.5	3
1173	Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo. Frontiers in Oncology, 2022, 12, .	1.3	4
1174	Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry. Frontiers in Oncology, 2022, 12, .	1.3	6
1175	NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis. Frontiers in Oncology, 2022, 12, .	1.3	1
1176	THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA. Blood, 2022, , .	0.6	7
1177	Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial. , 2022, 10, e004445.		5
1178	Clinical practice of precision medicine in lymphoma. Clinical and Translational Discovery, 2022, 2, .	0.2	0
1179	Clinical Manifestations and Surgical Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma: Beyond the NCCN Guidelines. Annals of Surgical Oncology, 0, , .	0.7	4
1180	Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real-life study. Pediatric Blood and Cancer, 0, , .	0.8	4
1182	Knockdown of LMNB1 Inhibits the Proliferation of Lung Adenocarcinoma Cells by Inducing DNA Damage and Cell Senescence. Frontiers in Oncology, 0, 12, .	1.3	8
1183	The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity. Scientific Reports, 2022, 12, .	1.6	10
1184	A Better Treatment for Advanced-Stage Hodgkin's Lymphoma?. New England Journal of Medicine, 2022, 387, 370-372.	13.9	4
1185	Brentuximab vedotin-associated diabetic ketoacidosis: a case report. International Journal of Diabetes in Developing Countries, 2023, 43, 120-124.	0.3	5
1186	Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy. Nature Communications, 2022, 13, .	5.8	14
1187	CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Frontiers in Immunology, 0, 13, .	2.2	48
1188	Antibody-Drug Conjugates Containing Payloads from Marine Origin. Marine Drugs, 2022, 20, 494.	2.2	7
1189	Cancer Immunotherapy: Diverse Approaches and Obstacles. Current Pharmaceutical Design, 2022, 28, 2387-2403.	0.9	4
1190	Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (Breach): A Multicenter, Open-Label, Randomized, Phase II Trial. Journal of Clinical Oncology, 2023, 41, 327-335.	0.8	19

#	ARTICLE	IF	CITATIONS
1191	Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. <i>Leukemia and Lymphoma</i> , 0, , 1-9.	0.6	1
1192	IL-2/IL-2R signaling and IL-2-targeted therapy in anaplastic large cell lymphoma. , 0, , .		0
1193	Serum and Mucosal CD30 in Pediatric Inflammatory Bowel Diseases: Useful Biomarker for Diagnosis and Disease Activity Monitoring?. <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	1
1194	Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 5378.	1.0	1
1195	Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1428-1442.	1.3	1
1196	One-Step Conversion of NHS Esters to Reagents for Site-Directed Labeling of IgG Antibodies. <i>Bioconjugate Chemistry</i> , 2022, 33, 1811-1817.	1.8	8
1197	The forgotten survivor: A comprehensive review on <sc>Non-Hodgkin</sc> lymphoma survivorship. <i>American Journal of Hematology</i> , 2022, 97, 1627-1637.	2.0	3
1198	The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy. <i>Journal of Cutaneous Pathology</i> , 2023, 50, 72-95.	0.7	2
1199	A preliminary study for the development of cleavable linkers using activatable fluorescent probes targeting leucine aminopeptidase. <i>Analyst, The</i> , 2022, 147, 5386-5394.	1.7	3
1202	Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. <i>Genes</i> , 2022, 13, 2065.	1.0	19
1203	Assessment of Crosslinkers between Peptide Antigen and Carrier Protein for Fusion Peptide-Directed Vaccines against HIV-1. <i>Vaccines</i> , 2022, 10, 1916.	2.1	0
1204	Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma. <i>International Immunopharmacology</i> , 2023, 114, 109521.	1.7	2
1205	Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. <i>Cancer</i> , 2023, 129, 283-295.	2.0	27
1206	Instability Challenges and Stabilization Strategies of Pharmaceutical Proteins. <i>Pharmaceutics</i> , 2022, 14, 2533.	2.0	12
1207	Development of therapeutic antibodies for the treatment of diseases. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	19
1208	Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 763-794.	0.5	8
1209	Bioactive Glasses as Carriers of Cancer-Targeted Drugs: Challenges and Opportunities in Bone Cancer Treatment. <i>Materials</i> , 2022, 15, 9082.	1.3	5
1210	Frequent CD30 Expression in an Emerging Group of Mesenchymal Tumors With NTRK, BRAF, RAF1, or RET Fusions. <i>Modern Pathology</i> , 2023, 36, 100083.	2.9	5

#	ARTICLE	IF	CITATIONS
1211	Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy. <i>AboutOpen</i> , 0, 10, 6-12.	0.2	1
1212	The Chemokine CCL17/TARC as a Biomarker in Hodgkin Lymphoma. <i>European Medical Journal Hematology</i> , 0, , 25-29.	0.0	1
1213	Cancer immunotherapy via nucleic acid aptamers. , 2023, , 317-346.		0
1214	Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. <i>Cancers</i> , 2023, 15, 713.	1.7	25
1215	Development of Next-Generation Antibody Therapeutics Using DDS and Molecular Imaging. , 2023, , 1-31.		0
1216	Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103923.	2.0	1
1217	First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors. <i>JCO Precision Oncology</i> , 2023, , .	1.5	1
1218	Central Nervous System Progression/Relapse in Mature T- and NK-Cell Lymphomas. <i>Cancers</i> , 2023, 15, 925.	1.7	2
1219	Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2023, 36, 101442.	0.7	2
1220	Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature. <i>European Urology Open Science</i> , 2023, 49, 100-103.	0.2	5
1221	Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs. <i>Journal of Controlled Release</i> , 2023, 355, 515-527.	4.8	1
1223	Integrating antibody drug conjugates in the management of gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 420-429.	1.2	8
1224	Targeted therapy. , 2023, , 459-488.		0
1227	The major clinical components of cancer immunotherapy (modulating cell-mediated immune) Tj ETQq1 1 0.784314 rgBT /Overlock 10		0
1233	Hematopoietic Cell Transplantation for Hodgkin Lymphoma. , 2024, , 357-370.		0
1244	Polymer-mediated nanoformulations: a promising strategy for cancer immunotherapy. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2024, 397, 1311-1326.	1.4	0
1260	Monoclonal Antibodies: From Structure to Therapeutic Application. , 2024, , 165-207.		0
1262	Nonclinical Development of Oncology Drugs. , 2024, , 721-742.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------